[
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy positive",
        "Consider preoperative chemotherapy",
        "Yes, preoperative chemotherapy",
        "cN+ converts to clinically node negative",
        "SLNB (category 2B)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "Progression",
        "Local: RT (if feasible) ± chemotherapy"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)",
        "Definitive therapy for thoracic disease feasible",
        "Consider systemic therapy and restaging to confirm non-progression or Proceed to definitive therapy",
        "T1–3, N1",
        "Pathologic mediastinal nodal evaluation and Chemoradiation (preferred) or Surgical resection or Definitive RT",
        "Definitive local therapy for metastatic site if not already given",
        "Consider systemic therapy, if not already given"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
        "No",
        "ALND level I/II"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R2",
        "Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Postmenopausal",
        "pT1-3 AND pN0 or pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm or pN1mi (≥2 mm axillary node metastases) or pN1 (1–3 positive nodes)",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Not done",
        "Adjuvant chemotherapy followed by endocrine therapy (category 1) or Adjuvant endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N1 nodes positive, M0",
        "Operable",
        "Surgical resectionl + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
        "No",
        "ALND level I/II"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "Progression",
        "Local: RT (if feasible) ± chemotherapy"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Superior sulcus tumor",
        "Treatment (NSCL-6)",
        "Superior sulcus tumor (T3 invasion, N0–1)",
        "Preoperative concurrent chemoradiation",
        "Surgery + Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Preferred: Osimertinib",
        "Progression",
        "Subsequent Therapy (NSCL-22)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T2a–3, N0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably SABR",
        "Consider adjuvant chemotherapyp for high-risk stage II",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "No apparent progression",
        "Surgery",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-negative/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively) and/or Adjuvant capecitabine (6–8 cycles) and/or Adjuvant olaparib for 1 year if germline BRCA1/2 mutation (category 1)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy (NSCL-K 3 of 5)",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and Prior endocrine therapy within 1 y",
        "Postmenopausal",
        "Systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Other Recommended: Amivantamab-vmjw + lazertinib (category 1)",
        "Progression: Subsequent Therapy (NSCL-22)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by crizotinib",
        "Progression",
        "Subsequent Therapy (NSCL-29)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "Smoking cessation advice, counseling, and pharmacotherapy"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-positive/ HER2-negative",
        "ypT0N0 or pCR",
        "Adjuvant endocrine therapy (category 1)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Preferred Capmatinib or Tepotinib",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-negative/ HER2-negative",
        "ypT0N0 or pCR",
        "For high-risk. Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Micrometastases seen in SLN",
        "No further axillary surgery"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably SABR",
        "Surveillance (NSCL-17)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "Visceral crisis",
        "Consider initial systemic therapy",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression",
        "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
        "Alternate systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-positive",
        "BINV-9",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor 0.6–1.0 cm",
        "Consider adjuvant chemotherapy with trastuzumab"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N0–1",
        "Initial Treatment (NSCL-12)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "No apparent progression",
        "Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Other Recommended: Erlotinib or Gefitinib or Dacomitinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Disease outside of chest",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive",
        "ROS1 rearrangement",
        "ROS1 rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by entrectinibr (preferred), crizotinib (preferred), repotrectinibr (preferred), or ceritinib",
        "Progression",
        "Subsequent Therapy (NSCL-31)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Preferred Capmatinib or Tepotinib",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
        "ER-positive and/or PR-positive or ER-negative and PR-negative",
        "Favorable Histologies (BINV-11)",
        "Pure tubular • Pure mucinous • Pure cribriform",
        "ER-positive and/or PR-positive, HER2-negative",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "1–2.9 cm",
        "Consider adjuvant endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
        "ER-positive and/or PR-positive or ER-negative and PR-negative",
        "Favorable Histologies (BINV-11)",
        "Pure tubular • Pure mucinous • Pure cribriform",
        "ER-positive and/or PR-positive, HER2-negative",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "≥3 cm",
        "Adjuvant endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Preferred: Osimertinib (category 1)",
        "Progression: Subsequent Therapy (NSCL-22)"
    ],
    [
        "Clinical suspicion of Paget disease",
        "Clinical breast exam, Diagnostic bilateral mammogram, ultrasound as necessary",
        "Examination and imaging negative for breast lesion",
        "PAGET-2"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Negative axillary nodes and tumor ≤5 cm and margins ≥1 mm",
        "No RT"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and PR-negative; HER2-positive",
        "BINV-26",
        "Systemic therapy + HER2-targeted therapy",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression",
        "Alternate systemic therapy + HER2-targeted therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further HER2-targeted therapy and continue supportive care (NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Multiple lung cancers",
        "Treatment (NSCL-12)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Micrometastases seen in SLN",
        "No further axillary surgery"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive",
        "EGFR exon 20 insertion mutation",
        "Amivantamab-vmjw + carboplatin/pemetrexed (nonsquamous) (category 1) (preferred)",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Preferred: Capmatinib or Tepotinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Pretreatment Evaluation (NSCL-8)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered prior to first-line systemic therapy",
        "FIRST-LINE THERAPY",
        "Other Recommended: Systemic Therapy for Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Dabrafenib + trametinib or Encorafenib + binimetinib",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Premenopausal",
        "Ovarian ablation or suppression + systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N1 nodes positive, M0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeonI and those who decline surgery after thoracic surgical consultation",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1 stage III; category 2A stage II) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1 stage III; category 2A stage II)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Workup • History and physical exam • Imaging: ▸ Diagnostic bilateral mammogram ▸ Ultrasound as necessary ▸ Breast MRI (optional), with special consideration for mammographically occult tumors • Pathology review • Determination of tumor estrogen/ progesterone receptor (ER/PR) status and HER2 status • Genetic counseling and testing if patient is at risk for hereditary breast cancer, has triple-negative breast cancer (TNBC) (at any age), or is a candidate for adjuvant olaparib • Address fertility and sexual health concerns as appropriate • Pregnancy test in all patients of childbearing potential (If pregnant, see PREG-1) • Assess for distress • Consider additional imaging studies only in the presence of signs and symptoms of metastatic disease and for patients who are clinically high risk (BINV-18)",
        "If indicated: • Chest x-ray (with abdominal shielding) • Abdominal ultrasound to assess liver metastases • Consider non-contrast MRI of spine if indicated to assess for bone metastases",
        "If pregnant with confirmed breast cancer; No distant metastases on staging",
        "Second trimester/ Early third trimester",
        "Mastectomy or BCS + axillary staging",
        "Adjuvant chemotherapy ± RT postpartum ± Adjuvant endocrine therapy postpartum"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
        "Yes to all",
        "Consider no further axillary surgery"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IVA (M1b)",
        "Pretreatment Evaluation (NSCL-15)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R2",
        "Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
        "Yes to all",
        "No further axillary surgery"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Micrometastases seen in SLN",
        "No further axillary surgery"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-positive",
        "BINV-24",
        "Systemic therapy + HER2-targeted therapy or Endocrine therapy ± HER2-targeted therapy (if premenopausal, consider ovarian ablation or suppression)",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression (BINV-25)",
        "Progression on first-line endocrine therapy ± HER2-targeted therapy",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens ± HER2-targeted therapy or Symptomatic visceral disease",
        "Systemic therapy + HER2-targeted therapy until progression",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further HER2-targeted therapy and continue supportive care",
        "See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T2a–3, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if plannedp",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N0–1",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N0–1",
        "Initial Treatment (NSCL-12)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Postmenopausal",
        "pT1-3 AND pN0 or pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm or pN1mi (≥2 mm axillary node metastases) or pN1 (1–3 positive nodes)",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Recurrence score ≥26",
        "Adjuvant chemotherapy followed by endocrine therapy (category 1)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Definitive concurrent chemoradiationm,s (category 1) or Systemic",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-positive",
        "BINV-24",
        "Systemic therapy + HER2-targeted therapy or Endocrine therapy ± HER2-targeted therapy (if premenopausal, consider ovarian ablation or suppression)",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression (BINV-25)",
        "Progression on systemic therapy + HER2-targeted therapy",
        "Alternate systemic therapy + HER2-targeted therapy"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above",
        "PD-L1 POSITIVE (≥1%)",
        "PS 3–4",
        "Best supportive care (NCCN Guidelines for Palliative Care)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Negative axillary nodes and tumor >5 cm",
        "Consider RT to chest wall ± comprehensive RNI (including any portion of the undissected axilla at risk)."
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Contralateral mediastinal node positive (T4, N3)",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R1",
        "Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-negative/ HER2-positive",
        "ypT0N0 or pCR",
        "Complete up to 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-positive",
        "BINV-9",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN+ (≥1 ipsilateral metastases >2 mm)",
        "Adjuvant chemotherapy with trastuzumab (category 1)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "DCIS Tis,N0,M0, Encapsulated or solid papillary carcinoma (SPC)",
        "History and physical exam • Diagnostic bilateral mammogram • Pathology review • Determination of tumor estrogen receptor (ER) status • Genetic counseling for patients at risk of hereditary breast cancer • Breast MRI as indicated",
        "Total mastectomy with sentinel lymph node biopsy (SLNB) ± reconstruction",
        "Postsurgical Treatment (DCIS-2)",
        "Risk reduction therapy for ipsilateral breast following BCS: • Consider endocrine therapy for 5 years for patients with ER-positive DCIS, if ➤ Treated with BCS and RT (category 1) ➤ Treated with excision alone • Endocrine therapy ➤ Tamoxifen for premenopausal patients ➤ Tamoxifen or aromatase inhibitor for postmenopausal patients with some advantage for aromatase inhibitor therapy in patients <60 years or with concerns for thromboembolism Risk reduction therapy for contralateral breast: • Counseling regarding risk reduction",
        "Interval history and physical exam every 6–12 mo for 5 y, then annually"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
        "No",
        "ALND level I/II"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N2–3",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered prior to first-line systemic therapy",
        "First-Line Therapy",
        "Useful in Certain Circumstances Cabozantinib",
        "Progression",
        "Subsequent Therapy",
        "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "cT3, cN0, and ypN0: Consider RT to the chest wall + comprehensive RNI with inclusion of any portion of the undissected axilla at risk."
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-positive",
        "BINV-9",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN+ (≥1 ipsilateral metastases >2 mm)",
        "or Adjuvant chemotherapy with trastuzumab + pertuzumab (category 1, preferred)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Contralateral mediastinal node negative",
        "Ipsilateral mediastinal node negative (T4, N0–1)",
        "Treatment for Stage IIIA (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Systemic therapy or Concurrent chemoradiation",
        "Surgical reevaluation including chest CT ± PET/CT",
        "Surgery",
        "Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "Visceral crisis",
        "Consider initial systemic therapy",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression",
        "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
        "Alternate systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably SABR",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-negative",
        "BINV-10",
        "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
        "pN+ (≥1 ipsilateral metastases >2 mm)",
        "Adjuvant chemotherapy (category 1)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm and pN0",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Recurrence score 16–25",
        "Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by osimertinib (preferred) or amivantamab-vmjw + lazertinib",
        "Progression: Subsequent Therapy (NSCL-22)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive",
        "EGFR exon 20 insertion mutation",
        "Amivantamab-vmjw + carboplatin/pemetrexed (nonsquamous) (category 1) (preferred)",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Lung nodules in asymptomatic, high-risk patients detected during lung cancer screening with LDCT",
        "NCCN Guidelines for Lung Cancer Screening"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Micrometastases seen in SLN",
        "No further axillary surgery"
    ],
    [
        "Incidental finding of nodule suspicious for lung cancer",
        "Multidisciplinary evaluation, Smoking cessation counseling",
        "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
        "Subsolid nodules Follow-up (DIAG-3)",
        "Incidental finding: subsolid nodule(s) on chest CT",
        "Solitary pure ground-glass nodules",
        "<6 mm No routine follow-up"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-positive/ HER2-positive",
        "ypT0N0 or pCR",
        "Endocrine therapy (category 1) + complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy (NSCL-K 3 of 5)",
        "Progression",
        "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
        "Systemic therapy, Progression (NSCL-K 4 of 5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN1mi (≤2 mm axillary node metastasis) or pN1 (1–3 positive nodes)",
        "Assess to determine if candidate for chemotherapy",
        "Not a candidate for chemotherapy",
        "Adjuvant endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered prior to first-line systemic therapy",
        "First-Line Therapy",
        "Preferred Selpercatinib or Pralsetinib",
        "Progression",
        "Subsequent Therapy",
        "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "No apparent progression",
        "Surgery",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered prior to first-line systemic therapy",
        "First-Line Therapy",
        "Other Recommended: Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Progression",
        "Preferred: Selpercatinib or Pralsetinib; Useful in Certain Circumstances: Cabozantinib",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N2–3",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive",
        "NTRK1/2/3 gene fusion",
        "NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy",
        "Preferred: Larotrectinibrr or Entrectinibrr or Repotrectinibrr",
        "Progression",
        "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R1",
        "Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-positive/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant endocrine therapy (category 1) + adjuvant olaparib if germline BRCA1/2 mutation CPS+EG score ≥3, and residual disease (category 1). Select patients may be eligible for adjuvant abemaciclib, see BINV-K for eligibility criteria."
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
        "Yes to all",
        "No further axillary surgery"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and Prior endocrine therapy within 1 y",
        "Premenopausal",
        "Ovarian ablation or suppression + systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "H&P (include performance status + weight loss)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "Use the 5 A's Framework: Ask, Advise, Assess, Assist, Arrange"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Other Recommended: Osimertinib + pemetrexed + (cisplatin or carboplatin) (nonsquamous) (category 1)",
        "Progression, Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive",
        "ROS1 rearrangement",
        "ROS1 rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by entrectinibr (preferred), crizotinib (preferred), repotrectinibr (preferred), or ceritinib",
        "Progression",
        "Subsequent Therapy (NSCL-31)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Treatment of Local and Regional Recurrence (BINV-19) and Supportive care",
        "Treatment of Local Recurrence: In-breast or Chest wall recurrence (Without clinically overt axillary recurrence)",
        "INITIAL (PRIOR SURGERY): Mastectomy",
        "Prior RT: No",
        "Surgical resection if feasible + surgical axillary staging + postmastectomy radiotherapy (PMRT)",
        "Consider appropriate systemic therapy (See BINV-K, BINV-L, BINV-P, BINV-Q)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IA, peripheral (T1abc, N0)",
        "Pretreatment Evaluation (NSCL-2)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by alectinib (preferred) or brigatinib (preferred) or lorlatinib (preferred) or ceritinib or crizotinib",
        "Progression",
        "Subsequent Therapy (NSCL-28)"
    ],
    [
        "Incidental finding of nodule suspicious for lung cancer",
        "Multidisciplinary evaluation, Smoking cessation counseling",
        "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
        "Subsolid nodules Follow-up (DIAG-3)",
        "Incidental finding: subsolid nodule(s) on chest CT",
        "Multiple subsolid nodules",
        "<6 mm • CT at 3–6 mo • If stable, consider CT at 2 and 4 y"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
        "ER-positive and/or PR-positive or ER-negative and PR-negative",
        "Favorable Histologies (BINV-11)",
        "Pure tubular • Pure mucinous • Pure cribriform",
        "ER-positive and/or PR-positive, HER2-negative",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "<1 cm",
        "Consider adjuvant endocrine therapy for risk reduction",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by afatinib (preferred) or osimertinib (preferred) or erlotinib or gefitinib or dacomitinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N1 nodes positive, M0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeonI and those who decline surgery after thoracic surgical consultation",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1 stage III; category 2A stage II) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1 stage III; category 2A stage II)",
        "Surveillance (NSCL-17)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T2a–3, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if plannedp",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Medically inoperable, high surgical risk as determined by thoracic surgeon, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably stereotactic ablative radiotherapy (SABR)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Operable",
        "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive",
        "EGFR exon 20 insertion mutation",
        "Systemic therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Progression",
        "Amivantamab-vmjw",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Negative axillary nodes",
        "Consider APBI/PBI in selected patients who are low risk (category 1)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Progression",
        "Preferred: Fam-trastuzumab deruxtecan-nxki or Other Recommended: Ado-trastuzumab emtansine",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N0–1",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Unresectable disease",
        "Treatment (NSCL-7)",
        "Stage IIIA (T4, N0–1) unresectable",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1) or Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "cN+ and ypN0: Strongly consider RT to the chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk."
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Premenopausal",
        "Selective ER modulators",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-negative",
        "BINV-10",
        "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor ≤0.5 cm",
        "pN1mi",
        "Consider adjuvant chemotherapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-negative/ HER2-negative",
        "ypT0N0 or pCR",
        "For high-risk. Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-positive",
        "BINV-9",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN+ (≥1 ipsilateral metastases >2 mm)",
        "Adjuvant chemotherapy with trastuzumab (category 1)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Treatment of Local and Regional Recurrence (BINV-19) and Supportive care",
        "Treatment of Local Recurrence: In-breast or Chest wall recurrence (Without clinically overt axillary recurrence)",
        "INITIAL (PRIOR SURGERY): BCS",
        "Prior RT: No",
        "Repeat BCS + surgical axillary staging if no prior ALND + RT",
        "Consider appropriate systemic therapy (See BINV-K, BINV-L, BINV-P, BINV-Q)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Preferred: Osimertinib",
        "Progression",
        "Subsequent Therapy (NSCL-22)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive",
        "NTRK1/2/3 gene fusion",
        "NTRK1/2/3 gene fusion discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by larotrectinib, entrectinib, or repotrectinib",
        "Progression",
        "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-positive",
        "BINV-9",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN+ (≥1 ipsilateral metastases >2 mm)",
        "or Adjuvant chemotherapy with trastuzumab + pertuzumab (category 1, preferred)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N2–3",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-positive",
        "BINV-5",
        "Ductal/NST • Lobular • Mixed • Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pNmi (≤2 mm axillary node metastasis)",
        "Tumor ≤0.5 cm",
        "pN1mi",
        "Adjuvant endocrine therapy or Adjuvant chemotherapy with trastuzumab and endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive",
        "NTRK1/2/3 gene fusion",
        "NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances: Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Larotrectinib or Entrectinib or Repotrectinib",
        "Progression",
        "Repotrectinib (if not previously given) or Systemic Therapy, Subsequent (NSCL-K 4 of 5)",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by osimertinib (preferred)",
        "Progression",
        "Subsequent Therapy (NSCL-22)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Operable",
        "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Stable or very slow-growing disease",
        "Observation",
        "Surveillance",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Operable",
        "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Adjuvant systemic therapy (BINV-16) + WBRT",
        "HR-positive/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant endocrine therapy (category 1) + adjuvant olaparib if germline BRCA1/2 mutation CPS+EG score ≥3, and residual disease (category 1). Select patients may be eligible for adjuvant abemaciclib, see BINV-K for eligibility criteria."
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Premenopausal",
        "Ovarian ablation or suppression + systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
        "Alternate systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered prior to first-line systemic therapy",
        "First-Line Therapy",
        "Other Recommended: Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Progression",
        "Preferred: Selpercatinib or Pralsetinib; Useful in Certain Circumstances: Cabozantinib",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-positive",
        "BINV-24",
        "Systemic therapy + HER2-targeted therapy or Endocrine therapy ± HER2-targeted therapy (if premenopausal, consider ovarian ablation or suppression)",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression (BINV-25)",
        "Progression on systemic therapy + HER2-targeted therapy",
        "Continue HER2-targeted therapy until progression",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further HER2-targeted therapy and continue supportive care",
        "See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-positive",
        "BINV-9",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor ≤0.5 cm",
        "pN0 Consider adjuvant chemotherapy with trastuzumab (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-negative",
        "BINV-10",
        "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor ≤0.5 cm",
        "pN1mi",
        "Consider adjuvant chemotherapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N2–3",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IA, peripheral (T1abc, N0)",
        "Pretreatment Evaluation (NSCL-2)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above",
        "PD-L1 POSITIVE (≥1%)",
        "PS 0–2",
        "Biomarker-directed therapy (NSCL-J 2 of 6)",
        "Progression",
        "Systemic Therapy (NSCL-K 1 of 5) or Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Treatment of Local and Regional Recurrence (BINV-19) and Supportive care",
        "Treatment of Local Recurrence: In-breast or Chest wall recurrence (Without clinically overt axillary recurrence)",
        "INITIAL (PRIOR SURGERY): BCS",
        "Prior RT: Yes",
        "Total mastectomy + surgical axillary staging if no prior ALND + repeat RT if feasible",
        "Consider appropriate systemic therapy (See BINV-K, BINV-L, BINV-P, BINV-Q)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Preferred: Capmatinib or Tepotinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Other Recommended: Erlotinib or Gefitinib or Dacomitinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above",
        "PD-L1 POSITIVE (≥1%)",
        "PS 0–2",
        "Biomarker-directed therapy (NSCL-J 2 of 6)",
        "Response or stable disease",
        "Continuation maintenance"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Preferred: Osimertinib",
        "Progression",
        "Subsequent Therapy (NSCL-22)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
        "ER-positive and/or PR-positive or ER-negative and PR-negative",
        "Favorable Histologies (BINV-11)",
        "Pure tubular • Pure mucinous • Pure cribriform",
        "ER-positive and/or PR-positive, HER2-negative",
        "pN+ (≥1 ipsilateral metastases >2 mm)",
        "Adjuvant endocrine therapy ± adjuvant chemotherapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Negative axillary nodes",
        "Consider omitting breast irradiation if adjuvant endocrine therapy is planned and following criteria are met (category 1): 1) ≥70 y, HR+, HER2-negative, cN0, pT1 2) ≥65 y, HR+, HER2-negative, pN0, pT ≤3 cm"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N0–1",
        "Initial Treatment (NSCL-12)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by selpercatinib (preferred), pralsetinib (preferred), cabozantinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Unresectable disease",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins positive",
        "R1",
        "Resection + chemotherapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Contralateral mediastinal node negative",
        "Ipsilateral mediastinal node negative (T4, N0–1)",
        "Treatment for Stage IIIA (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Systemic therapy or Concurrent chemoradiation",
        "Surgical reevaluation including chest CT ± PET/CT",
        "Surgery",
        "Margins positive (R1, R2)",
        "Resection and/or RT boost",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "DCIS Tis,N0,M0, Encapsulated or solid papillary carcinoma (SPC)",
        "History and physical exam • Diagnostic bilateral mammogram • Pathology review • Determination of tumor estrogen receptor (ER) status • Genetic counseling for patients at risk of hereditary breast cancer • Breast MRI as indicated",
        "Breast-conserving surgery (BCS) without lymph node surgery",
        "Whole breast radiation therapy (WBRT) (category 1) with or without boost to tumor bed or Accelerated partial breast irradiation/partial breast irradiation (APBI/PBI) or No RT (category 2B)",
        "Postsurgical Treatment (DCIS-2)",
        "Risk reduction therapy for ipsilateral breast following BCS: • Consider endocrine therapy for 5 years for patients with ER-positive DCIS, if ➤ Treated with BCS and RT (category 1) ➤ Treated with excision alone • Endocrine therapy ➤ Tamoxifen for premenopausal patients ➤ Tamoxifen or aromatase inhibitor for postmenopausal patients with some advantage for aromatase inhibitor therapy in patients <60 years or with concerns for thromboembolism Risk reduction therapy for contralateral breast: • Counseling regarding risk reduction",
        "Interval history and physical exam every 6–12 mo for 5 y, then annually"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R1",
        "Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)",
        "Definitive therapy for thoracic disease not feasible",
        "Systemic Therapy for Metastatic Disease"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "Use the 5 A's Framework: Ask, Advise, Assess, Assist, Arrange"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
        "No",
        "ALND level I/II"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN1mi (≤2 mm axillary node metastasis) or pN1 (1–3 positive nodes)",
        "Assess to determine if candidate for chemotherapy",
        "If candidate for chemotherapy consider gene expression assay to assess prognosis",
        "Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and PR-negative; HER2-negative",
        "BINV-27",
        "Systemic therapy",
        "Continue therapy until progression or unacceptable toxicity",
        "Alternative systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and continue supportive care (NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Micrometastases seen in SLN",
        "No further axillary surgery"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IIB (T3 invasion, N0); Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Pretreatment Evaluation (NSCL-5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
        "No",
        "ALND level I/II"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances: Crizotinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-positive/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant endocrine therapy (category 1) + adjuvant olaparib if germline BRCA1/2 mutation CPS+EG score ≥3, and residual disease (category 1). Select patients may be eligible for adjuvant abemaciclib, see BINV-K for eligibility criteria."
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-positive",
        "BINV-9",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor ≤0.5 cm",
        "pN0 Consider adjuvant chemotherapy with trastuzumab (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Useful in Certain Circumstances Crizotinib",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N0–1",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably SABR",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N2–3",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Disease outside of chest",
        "Systemic therapy for metastatic disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)",
        "Definitive therapy for thoracic disease feasible",
        "Consider systemic therapy and restaging to confirm non-progression or Proceed to definitive therapy",
        "T1–3, N2, T4, N0–2",
        "Definitive chemoradiation"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by capmatinib (preferred) or tepotinib (preferred) or crizotinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Disease outside of chest",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "cT4, any N: RT is indicated to the chest wall + comprehensive RNI with inclusion of any portion of the undissected axilla at risk."
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Adjuvant systemic therapy (BINV-16) + WBRT",
        "HR-negative/ HER2-negative",
        "ypT0N0 or pCR",
        "For high-risk. Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy positive",
        "Consider preoperative chemotherapy",
        "No preoperative chemotherapy",
        "ALND level I/II"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered prior to first-line systemic therapy",
        "First-Line Therapy",
        "Preferred Selpercatinib or Pralsetinib",
        "Progression",
        "Subsequent Therapy",
        "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Preferred: Afatinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Progression",
        "Preferred: Fam-trastuzumab deruxtecan-nxki or Other Recommended: Ado-trastuzumab emtansine",
        "Progression",
        "PS 3–4",
        "Best supportive care: NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
    ],
    [
        "DCIS Tis,N0,M0, Encapsulated or solid papillary carcinoma (SPC)",
        "History and physical exam • Diagnostic bilateral mammogram • Pathology review • Determination of tumor estrogen receptor (ER) status • Genetic counseling for patients at risk of hereditary breast cancer • Breast MRI as indicated",
        "Total mastectomy with sentinel lymph node biopsy (SLNB) ± reconstruction",
        "Postsurgical Treatment (DCIS-2)",
        "Risk reduction therapy for ipsilateral breast following BCS: • Consider endocrine therapy for 5 years for patients with ER-positive DCIS, if ➤ Treated with BCS and RT (category 1) ➤ Treated with excision alone • Endocrine therapy ➤ Tamoxifen for premenopausal patients ➤ Tamoxifen or aromatase inhibitor for postmenopausal patients with some advantage for aromatase inhibitor therapy in patients <60 years or with concerns for thromboembolism Risk reduction therapy for contralateral breast: • Counseling regarding risk reduction",
        "First mammogram 6–12 mo, after breast-conservation therapy (category 2B) and annually thereafter"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered prior to first-line systemic therapy",
        "Preferred Alectinibr (category 1) or Brigatinibr (category 1) or Lorlatinibr (category 1)",
        "Progression",
        "Subsequent Therapy (NSCL-28)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "Progression",
        "Systemic: Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN1mi (≤2 mm axillary node metastasis) or pN1 (1–3 positive nodes)",
        "Assess to determine if candidate for chemotherapy",
        "If candidate for chemotherapy consider gene expression assay to assess prognosis",
        "Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-positive/ HER2-negative",
        "ypT0N0 or pCR",
        "Adjuvant endocrine therapy (category 1)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm and pN0",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Recurrence score ≤15",
        "Adjuvant endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Progression",
        "Preferred: Fam-trastuzumab deruxtecan-nxki or Other Recommended: Ado-trastuzumab emtansine",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy (NSCL-K 3 of 5)",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "No apparent progression",
        "Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered prior to first-line systemic therapy",
        "FIRST-LINE THERAPY",
        "Preferred: Dabrafenib + trametinib or Encorafenib + binimetinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Adjuvant systemic therapy (BINV-16) + WBRT",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Treatment of Local and Regional Recurrence (BINV-19) and Supportive care",
        "Treatment of Local Recurrence: In-breast or Chest wall recurrence (Without clinically overt axillary recurrence)",
        "INITIAL (PRIOR SURGERY): Mastectomy",
        "Prior RT: Yes",
        "Surgical resection if feasible + surgical axillary staging if no prior ALND + repeat RT, if feasible",
        "Consider appropriate systemic therapy (See BINV-K, BINV-L, BINV-P, BINV-Q)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IVB (M1c) disseminated metastases",
        "Systemic Therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-negative/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively) and/or Adjuvant capecitabine (6–8 cycles) and/or Adjuvant olaparib for 1 year if germline BRCA1/2 mutation (category 1)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "≥4 positive axillary nodes",
        "RT to chest wall + comprehensive RNI (including any portion of the undissected axilla at risk) (category 1)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
        "ER-positive and/or PR-positive or ER-negative and PR-negative",
        "Favorable Histologies (BINV-11)",
        "Pure tubular • Pure mucinous • Pure cribriform",
        "ER-positive and/or PR-positive, HER2-negative",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "<1 cm",
        "Consider adjuvant endocrine therapy for risk reduction",
        "Follow-Up (BINV-17)"
    ],
    [
        "Clinical pathologic diagnosis of IBC",
        "History and physical exam by multidisciplinary team and obtain medical photography, CBC, Comprehensive metabolic panel, including LFTs and alkaline phosphatase, Pathology review, Determination of tumor ER/PR status and HER2 status, Fertility counseling if premenopausal, Genetic counseling if patient is at risk for hereditary breast cancer, Imaging: Bilateral diagnostic mammogram, ultrasound as necessary, Chest diagnostic CT ± contrast, Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast, Bone scan or FDG-PET/CT, Breast MRI (optional)",
        "Preoperative/Adjuvant Therapy Regimens (BINV-L)",
        "Response to preoperative therapy",
        "No response",
        "Consider additional systemic chemotherapy, and/or preoperative radiation.",
        "Patients may be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Response",
        "Total mastectomy + level I/II axillary dissection + RT to chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk ± delayed breast reconstruction",
        "Complete planned chemotherapy regimen course if not completed preoperatively plus endocrine treatment if ER-positive and/or PR-positive (sequential chemotherapy followed by endocrine therapy). Complete up to one year of HER2-targeted therapy if HER2-positive (category 1). May be administered concurrently with RT and with endocrine therapy if indicated."
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and Prior endocrine therapy within 1 y",
        "Premenopausal",
        "Ovarian ablation or suppression + systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm and pN0",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Not done",
        "Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-positive/ HER2-negative",
        "ypT0N0 or pCR",
        "Adjuvant endocrine therapy (category 1)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-positive",
        "BINV-5",
        "Ductal/NST • Lobular • Mixed • Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pNmi (≤2 mm axillary node metastasis)",
        "Tumor ≤0.5 cm",
        "pN0",
        "Consider adjuvant endocrine therapy or Consider adjuvant chemotherapy with trastuzumab (category 2B) and endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Operable",
        "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 3–4",
        "Best supportive care: NCCN Guidelines for Palliative Care"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-positive",
        "BINV-5",
        "Ductal/NST • Lobular • Mixed • Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pNmi (≤2 mm axillary node metastasis)",
        "Tumor >1 cm",
        "Adjuvant chemotherapy with trastuzumab (category 1) and endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by capmatinib (preferred) or tepotinib (preferred) or crizotinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Chest wall",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins positive",
        "R1",
        "Resection + chemotherapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Operable",
        "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by alectinib (preferred) or brigatinib (preferred) or lorlatinib (preferred) or ceritinib or crizotinib",
        "Progression",
        "Subsequent Therapy (NSCL-28)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-positive/ HER2-positive",
        "ypT0N0 or pCR",
        "Endocrine therapy (category 1) + complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Margins positive",
        "Re-excision to negative margins is preferred. If not feasible, then strongly consider RT to chest wall ± comprehensive RNI (including any portion of the undissected axilla at risk)."
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "Progression",
        "Local: RT (if feasible) ± chemotherapy"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Preferred: Capmatinib or Tepotinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by erlotinib or gefitinib or dacomitinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Trachea/carina or mediastinum",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Systemic therapy or Concurrent chemoradiation",
        "Surgical reevaluation including chest CT ± PET/CT",
        "Surgery",
        "Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by alectinib (preferred) or brigatinib (preferred) or lorlatinib (preferred) or ceritinib or crizotinib",
        "Progression",
        "Subsequent Therapy (NSCL-28)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "≥4 positive axillary nodes",
        "WBRT ± boost to tumor bed (category 1) + comprehensive RNI, including any portion of the undissected axilla at risk (category 1)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive",
        "NTRK1/2/3 gene fusion",
        "NTRK1/2/3 gene fusion discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by larotrectinib, entrectinib, or repotrectinib",
        "Progression",
        "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered prior to first-line systemic therapy",
        "FIRST-LINE THERAPY",
        "Other Recommended: Systemic Therapy for Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Dabrafenib + trametinib or Encorafenib + binimetinib",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Stage IIIA (T4, N0–1)",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins positive",
        "R2",
        "Resection + chemotherapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Adjuvant systemic therapy (BINV-16) + WBRT",
        "cN+ and ypN0: Adjuvant RT to the whole breast ± boost to the tumor bed; strongly consider comprehensive RNI with inclusion of any portion of the undissected axilla at risk."
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IVA (M1b)",
        "Pretreatment Evaluation (NSCL-15)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Contralateral mediastinal node negative",
        "Ipsilateral mediastinal node negative (T4, N0–1)",
        "Treatment for Stage IIIA (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins positive",
        "R2",
        "Resection + chemotherapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N0–1",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "Any cN0, ypN0: If axilla was assessed by SLNB or axillary node dissection"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above",
        "PD-L1 POSITIVE (≥1%)",
        "PS 3–4",
        "Best supportive care (NCCN Guidelines for Palliative Care)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably SABR",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IB, peripheral (T2a, N0); Stage I, central (T1abc–T2a, N0); Stage II (T1abc–T2ab, N1; T2b, N0); Stage IIB (T3, N0)f; Stage IIIA (T3, N1)",
        "Pretreatment Evaluation (NSCL-3)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "Chemistry profile"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive",
        "NTRK1/2/3 gene fusion",
        "NTRK1/2/3 gene fusion discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by larotrectinib, entrectinib, or repotrectinib",
        "Progression",
        "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "Pathology review"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy positive",
        "Consider preoperative chemotherapy",
        "Yes, preoperative chemotherapy",
        "cN+ remains clinically positive",
        "ALND level I/II"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy (NSCL-K 3 of 5)",
        "Progression",
        "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
        "Systemic therapy, Progression (NSCL-K 4 of 5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "cN+ and ypN0: Strongly consider RT to the chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk."
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN not identified",
        "ALND level I/II"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy (NSCL-K 3 of 5)",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Stage IIIA (T4, N0–1)",
        "Treatment (NSCL-7)",
        "Stage IIIA (T4, N0–1) unresectable",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1) or Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-positive",
        "BINV-9",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor >1 cm",
        "Adjuvant chemotherapy with trastuzumab (category 1)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
        "Yes to all",
        "No further axillary surgery"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by crizotinib",
        "Progression",
        "Subsequent Therapy (NSCL-29)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered prior to first-line systemic therapy",
        "FIRST-LINE THERAPY",
        "Useful in Certain Circumstances: Vemurafenib or dabrafenib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Pretreatment Evaluation (NSCL-8)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive",
        "ROS1 rearrangement",
        "ROS1 rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by entrectinibr (preferred), crizotinib (preferred), repotrectinibr (preferred), or ceritinib",
        "Progression",
        "Subsequent Therapy (NSCL-31)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Clinical pathologic diagnosis of IBC",
        "History and physical exam by multidisciplinary team and obtain medical photography, CBC, Comprehensive metabolic panel, including LFTs and alkaline phosphatase, Pathology review, Determination of tumor ER/PR status and HER2 status, Fertility counseling if premenopausal, Genetic counseling if patient is at risk for hereditary breast cancer, Imaging: Bilateral diagnostic mammogram, ultrasound as necessary, Chest diagnostic CT ± contrast, Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast, Bone scan or FDG-PET/CT, Breast MRI (optional)",
        "Preoperative/Adjuvant Therapy Regimens (BINV-L)",
        "Response to preoperative therapy",
        "No response",
        "Consider additional systemic chemotherapy, and/or preoperative radiation.",
        "Patients may be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "No response",
        "Individualized treatment"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Postmenopausal",
        "pT1-3 AND pN0 or pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm or pN1mi (≥2 mm axillary node metastases) or pN1 (1–3 positive nodes)",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Recurrence score <26",
        "Adjuvant endocrine therapy (category 1)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-positive",
        "BINV-24",
        "Systemic therapy + HER2-targeted therapy or Endocrine therapy ± HER2-targeted therapy (if premenopausal, consider ovarian ablation or suppression)",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression (BINV-25)",
        "Progression on systemic therapy + HER2-targeted therapy",
        "Continue HER2-targeted therapy until progression",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further HER2-targeted therapy and continue supportive care",
        "See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by dabrafenib + trametinib (preferred) or encorafenib + binimetinib (preferred)",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Contralateral mediastinal node negative",
        "Ipsilateral mediastinal node negative (T4, N0–1)",
        "Treatment for Stage IIIA (NSCL-7)",
        "Stage IIIA (T4, N0–1) unresectable",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1) or Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-positive",
        "BINV-5",
        "Ductal/NST • Lobular • Mixed • Micropapillary",
        "pN+ (≥1 ipsilateral metastases >2 mm)",
        "Adjuvant chemotherapy with trastuzumab (category 1) and endocrine therapy or Adjuvant chemotherapy with trastuzumab + pertuzumab (category 1, preferred) and endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Definitive concurrent chemoradiationm,s (category 1) or Systemic",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Progression",
        "Preferred: Fam-trastuzumab deruxtecan-nxki or Other Recommended: Ado-trastuzumab emtansine",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Contralateral mediastinal node negative",
        "Ipsilateral mediastinal node negative (T4, N0–1)",
        "Treatment for Stage IIIA (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Negative axillary nodes and tumor ≤5 cm and negative margins but <1 mm",
        "Consider RT to chest wall. For patients with additional high-risk features, consider addition of comprehensive RNI (including any portion of the undissected axilla at risk)."
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "Visceral crisis",
        "Consider initial systemic therapy",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Workup • History and physical exam • Imaging: ▸ Diagnostic bilateral mammogram ▸ Ultrasound as necessary ▸ Breast MRI (optional), with special consideration for mammographically occult tumors • Pathology review • Determination of tumor estrogen/ progesterone receptor (ER/PR) status and HER2 status • Genetic counseling and testing if patient is at risk for hereditary breast cancer, has triple-negative breast cancer (TNBC) (at any age), or is a candidate for adjuvant olaparib • Address fertility and sexual health concerns as appropriate • Pregnancy test in all patients of childbearing potential (If pregnant, see PREG-1) • Assess for distress • Consider additional imaging studies only in the presence of signs and symptoms of metastatic disease and for patients who are clinically high risk (BINV-18)",
        "If indicated: • Chest x-ray (with abdominal shielding) • Abdominal ultrasound to assess liver metastases • Consider non-contrast MRI of spine if indicated to assess for bone metastases",
        "If pregnant with confirmed breast cancer; No distant metastases on staging",
        "First trimester",
        "Discuss termination: Non-therapeutic",
        "Continuing pregnancy",
        "Mastectomy + axillary staging",
        "Begin adjuvant chemotherapy in second trimester ± RT postpartum ± Adjuvant endocrine therapy postpartum"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Trachea/carina or mediastinum",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins positive",
        "R2",
        "Resection + chemotherapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-negative",
        "BINV-10",
        "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
        "pN+ (≥1 ipsilateral metastases >2 mm)",
        "Adjuvant chemotherapy (category 1)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Preferred: Afatinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Operable",
        "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Adjuvant systemic therapy (BINV-16) + WBRT",
        "HR-positive/ HER2-positive",
        "ypT0N0 or pCR",
        "Endocrine therapy (category 1) + complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and Prior endocrine therapy within 1 y",
        "Premenopausal",
        "Ovarian ablation or suppression + systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "Progression",
        "Local: RT (if feasible) ± chemotherapy"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
        "Yes to all",
        "No further axillary surgery"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IIIB (T1–2, N3); Stage IIIC (T3, N3)",
        "Pretreatment Evaluation (NSCL-13)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances: Erlotinib + ramucirumab or Erlotinib + bevacizumab or Dacomitinib (category 1) or Afatinib (category 1) or Erlotinib (category 1) or Gefitinib (category 1)",
        "Progression: Subsequent Therapy (NSCL-23)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "No response to preoperative systemic therapy and/or tumor remains inoperable",
        "Consider additional systemic therapy and/or preoperative radiation",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-negative/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively) and/or Adjuvant capecitabine (6–8 cycles) and/or Adjuvant olaparib for 1 year if germline BRCA1/2 mutation (category 1)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Stable or very slow-growing disease",
        "Observation",
        "Surveillance",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances: Crizotinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R2",
        "Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "DCIS Tis,N0,M0, Encapsulated or solid papillary carcinoma (SPC)",
        "History and physical exam • Diagnostic bilateral mammogram • Pathology review • Determination of tumor estrogen receptor (ER) status • Genetic counseling for patients at risk of hereditary breast cancer • Breast MRI as indicated",
        "Breast-conserving surgery (BCS) without lymph node surgery",
        "Whole breast radiation therapy (WBRT) (category 1) with or without boost to tumor bed or Accelerated partial breast irradiation/partial breast irradiation (APBI/PBI) or No RT (category 2B)",
        "Postsurgical Treatment (DCIS-2)",
        "Risk reduction therapy for ipsilateral breast following BCS: • Consider endocrine therapy for 5 years for patients with ER-positive DCIS, if ➤ Treated with BCS and RT (category 1) ➤ Treated with excision alone • Endocrine therapy ➤ Tamoxifen for premenopausal patients ➤ Tamoxifen or aromatase inhibitor for postmenopausal patients with some advantage for aromatase inhibitor therapy in patients <60 years or with concerns for thromboembolism Risk reduction therapy for contralateral breast: • Counseling regarding risk reduction",
        "First mammogram 6–12 mo, after breast-conservation therapy (category 2B) and annually thereafter"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN1mi (≤2 mm axillary node metastasis) or pN1 (1–3 positive nodes)",
        "Assess to determine if candidate for chemotherapy",
        "Not a candidate for chemotherapy",
        "Adjuvant endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Postmenopausal",
        "Systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Clinical pathologic diagnosis of IBC",
        "History and physical exam by multidisciplinary team and obtain medical photography, CBC, Comprehensive metabolic panel, including LFTs and alkaline phosphatase, Pathology review, Determination of tumor ER/PR status and HER2 status, Fertility counseling if premenopausal, Genetic counseling if patient is at risk for hereditary breast cancer, Imaging: Bilateral diagnostic mammogram, ultrasound as necessary, Chest diagnostic CT ± contrast, Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast, Bone scan or FDG-PET/CT, Breast MRI (optional)",
        "Preoperative/Adjuvant Therapy Regimens (BINV-L)",
        "See IBC-2"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by capmatinib (preferred) or tepotinib (preferred) or crizotinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-positive/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant endocrine therapy (category 1) + adjuvant olaparib if germline BRCA1/2 mutation CPS+EG score ≥3, and residual disease (category 1). Select patients may be eligible for adjuvant abemaciclib, see BINV-K for eligibility criteria."
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-negative/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively) and/or Adjuvant capecitabine (6–8 cycles) and/or Adjuvant olaparib for 1 year if germline BRCA1/2 mutation (category 1)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered prior to first-line systemic therapy",
        "FIRST-LINE THERAPY",
        "Preferred: Dabrafenib + trametinib or Encorafenib + binimetinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy (NSCL-K 3 of 5)",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy positive",
        "Consider preoperative chemotherapy",
        "No preoperative chemotherapy",
        "ALND level I/II"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
        "Yes to all",
        "Consider no further axillary surgery"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Premenopausal",
        "Ovarian ablation or suppression + systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
        "Alternate systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "Chemistry profile"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-positive",
        "BINV-5",
        "Ductal/NST • Lobular • Mixed • Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pNmi (≤2 mm axillary node metastasis)",
        "Tumor 0.6–1.0 cm",
        "Adjuvant endocrine therapy or Adjuvant chemotherapy with trastuzumab and endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Incidental finding of nodule suspicious for lung cancer",
        "Multidisciplinary evaluation, Smoking cessation counseling",
        "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
        "Solid nodules Follow-up (DIAG-2)",
        "Incidental finding: solid nodule(s) on chest CT",
        "Low risk",
        "< 6 mm No routine follow-up"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Incidental finding of nodule suspicious for lung cancer",
        "Multidisciplinary evaluation, Smoking cessation counseling",
        "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
        "Solid nodules Follow-up (DIAG-2)",
        "Incidental finding: solid nodule(s) on chest CT",
        "Low risk",
        "> 8 mm Consider CT at 3 mo, FDG-PET/CT, or biopsy"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 positive",
        "Definitive concurrent chemoradiationm,s (category 1)",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN not identified",
        "ALND level I/II"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "Pathology review"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive",
        "EGFR exon 20 insertion mutation",
        "Systemic therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Progression",
        "Amivantamab-vmjw",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered prior to first-line systemic therapy",
        "FIRST-LINE THERAPY",
        "Useful in Certain Circumstances: Vemurafenib or dabrafenib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-negative/ HER2-negative",
        "ypT0N0 or pCR",
        "For high-risk. Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-positive/ HER2-negative",
        "ypT0N0 or pCR",
        "Adjuvant endocrine therapy (category 1)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm and pN0",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Recurrence score 16–25",
        "Adjuvant endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy (NSCL-K 3 of 5)",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "No response to preoperative systemic therapy and/or tumor remains inoperable",
        "Consider additional systemic therapy and/or preoperative radiation",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-positive/ HER2-negative",
        "ypT0N0 or pCR",
        "Adjuvant endocrine therapy (category 1)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
        "No",
        "ALND level I/II"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Micrometastases seen in SLN",
        "No further axillary surgery"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-negative",
        "BINV-10",
        "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor ≤0.5 cm",
        "pN0",
        "No adjuvant therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm and pN0",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Recurrence score ≥26",
        "Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Stage IIIA (T4, N0–1)",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Systemic therapy or Concurrent chemoradiation",
        "Surgical reevaluation including chest CT ± PET/CT",
        "Surgery",
        "Margins positive (R1, R2)",
        "Resection and/or RT boost",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor ≤0.5 cm and pN0",
        "Consider adjuvant endocrine therapy (category 2B)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-negative",
        "BINV-10",
        "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor >1 cm",
        "Adjuvant chemotherapy (category 1)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by dabrafenib + trametinib (preferred) or encorafenib + binimetinib (preferred)",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Useful in Certain Circumstances Crizotinib",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N0–1",
        "Initial Treatment (NSCL-12)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Progression",
        "Preferred: Fam-trastuzumab deruxtecan-nxki or Other Recommended: Ado-trastuzumab emtansine",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "1–3 positive axillary nodes",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive sentinel lymph nodes (SLNs) • WBRT planned",
        "Yes to all",
        "WBRT ± boost (use of comprehensive RNI with or without intentional inclusion of axilla at the discretion of the radiation oncologist) (category 1)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Preferred Capmatinib or Tepotinib",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above",
        "PD-L1 POSITIVE (≥1%)",
        "PS 0–2",
        "Biomarker-directed therapy (NSCL-J 2 of 6)",
        "Progression",
        "Systemic Therapy (NSCL-K 1 of 5) or Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "No response to preoperative systemic therapy and/or tumor remains inoperable",
        "Consider additional systemic therapy and/or preoperative radiation",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Medically inoperable, high surgical risk as determined by thoracic surgeon, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably SABR",
        "Consider adjuvant chemotherapy for high-risk stage II",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-negative/ HER2-positive",
        "ypT0N0 or pCR",
        "Complete up to 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-positive",
        "BINV-24",
        "Systemic therapy + HER2-targeted therapy or Endocrine therapy ± HER2-targeted therapy (if premenopausal, consider ovarian ablation or suppression)",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression (BINV-25)",
        "Progression on first-line endocrine therapy ± HER2-targeted therapy",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens ± HER2-targeted therapy or Symptomatic visceral disease",
        "Systemic therapy + HER2-targeted therapy until progression",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further HER2-targeted therapy and continue supportive care",
        "See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N1 nodes positive, M0",
        "Operable",
        "Surgical resectionl + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN2/pN3 (≥4 ipsilateral metastases >2 mm)",
        "Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation (category 1)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Operable",
        "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-positive",
        "BINV-5",
        "Ductal/NST • Lobular • Mixed • Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pNmi (≤2 mm axillary node metastasis)",
        "Tumor ≤0.5 cm",
        "pN1mi",
        "Adjuvant endocrine therapy or Adjuvant chemotherapy with trastuzumab and endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Chest wall",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins positive",
        "R2",
        "Resection + chemotherapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Unresectable disease",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Systemic therapy or Concurrent chemoradiation",
        "Surgical reevaluation including chest CT ± PET/CT",
        "Surgery",
        "Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm and pN0",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Not done",
        "Adjuvant endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Stage IIIA (T4, N0–1)",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Adjuvant systemic therapy (BINV-16) + WBRT",
        "Any ypN+: Adjuvant RT to the whole breast ± boost to the tumor bed; comprehensive RNI with inclusion of any portion of the undissected axilla at risk."
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
        "No",
        "ALND level I/II"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy (NSCL-K 3 of 5)",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above",
        "PD-L1 POSITIVE (≥1%)",
        "PS 0–2",
        "Biomarker-directed therapy (NSCL-J 2 of 6)",
        "Progression",
        "Systemic Therapy (NSCL-K 1 of 5) or Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Preferred: Capmatinib or Tepotinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N0–1",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "1–3 positive axillary nodes",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive sentinel lymph nodes (SLNs) • WBRT planned",
        "No",
        "WBRT with inclusion of any portion of the undissected axilla at risk ± boost to tumor bed (category 1). Strongly consider comprehensive RNI, including any portion of the undissected axilla."
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive",
        "EGFR exon 20 insertion mutation",
        "Systemic therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy",
        "Progression",
        "Amivantamab-vmjw",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by dabrafenib + trametinib (preferred) or encorafenib + binimetinib (preferred)",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm and pN0",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Not done",
        "Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Progression",
        "PS 0–2",
        "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
        "Systemic therapy, Progression (NSCL-K 4 of 5)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
        "ER-positive and/or PR-positive or ER-negative and PR-negative",
        "Favorable Histologies (BINV-11)",
        "Pure tubular • Pure mucinous • Pure cribriform",
        "ER-positive and/or PR-positive, HER2-negative",
        "pN+ (≥1 ipsilateral metastases >2 mm)",
        "Adjuvant endocrine therapy ± adjuvant chemotherapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered prior to first-line systemic therapy",
        "Other Recommended Ceritinibr (category 1)",
        "Progression",
        "Subsequent Therapy (NSCL-28)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Other Recommended: Amivantamab-vmjw + lazertinib (category 1)",
        "Progression: Subsequent Therapy (NSCL-22)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive",
        "NTRK1/2/3 gene fusion",
        "NTRK1/2/3 gene fusion discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by larotrectinib, entrectinib, or repotrectinib",
        "Progression",
        "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered prior to first-line systemic therapy",
        "First-Line Therapy",
        "Useful in Certain Circumstances Cabozantinib",
        "Progression",
        "Subsequent Therapy",
        "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N2–3",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-positive",
        "BINV-24",
        "Systemic therapy + HER2-targeted therapy or Endocrine therapy ± HER2-targeted therapy (if premenopausal, consider ovarian ablation or suppression)",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression (BINV-25)",
        "Progression on first-line endocrine therapy ± HER2-targeted therapy",
        "Consider alternate endocrine therapy, if not endocrine refractory ± HER2-targeted therapy"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Micrometastases seen in SLN",
        "No further axillary surgery"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm and pN0",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Recurrence score 16–25",
        "Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Negative axillary nodes",
        "WBRT ± boost to tumor bed, and consider comprehensive regional nodal irradiation (RNI) in patients with central/medial tumors, pT3 tumors, or pT2 tumors and one of the following high-risk features: grade 3, extensive lymphovascular invasion (LVI), or hormone-receptor (HR)-negative."
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-positive/ HER2-positive",
        "ypT0N0 or pCR",
        "Endocrine therapy (category 1) + complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IB, peripheral (T2a, N0); Stage I, central (T1abc–T2a, N0); Stage II (T1abc–T2ab, N1; T2b, N0); Stage IIB (T3, N0)f; Stage IIIA (T3, N1)",
        "Pretreatment Evaluation (NSCL-3)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "For tools to aid in the optimal assessment and management of NSCLC in older adults, see the NCCN Guidelines for Older Adult Oncology"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by osimertinib (preferred)",
        "Progression",
        "Subsequent Therapy (NSCL-22)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "No apparent progression",
        "Surgery",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IIB (T3 invasion, N0); Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Pretreatment Evaluation (NSCL-5)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Other Recommended: Osimertinib + pemetrexed + (cisplatin or carboplatin) (nonsquamous) (category 1)",
        "Progression, Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "Visceral crisis",
        "Consider initial systemic therapy",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Micrometastases seen in SLN",
        "No further axillary surgery"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
        "Yes to all",
        "Consider no further axillary surgery"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-positive/ HER2-positive",
        "ypT0N0 or pCR",
        "Endocrine therapy (category 1) + complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Contralateral mediastinal node positive (T4, N3)",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-negative",
        "BINV-10",
        "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor 0.6–1.0 cm",
        "Consider adjuvant chemotherapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)",
        "Definitive therapy for thoracic disease feasible",
        "Consider systemic therapy and restaging to confirm non-progression or Proceed to definitive therapy",
        "T1–3, N2, T4, N0–2",
        "Definitive chemoradiation"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN not identified",
        "ALND level I/II"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "No response to preoperative systemic therapy and/or tumor remains inoperable",
        "Consider additional systemic therapy and/or preoperative radiation",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-negative/ HER2-negative",
        "ypT0N0 or pCR",
        "For high-risk. Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances Crizotinibb (category 1)",
        "Progression",
        "Subsequent Therapy (NSCL-29)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T2a–3, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if plannedp",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered prior to first-line systemic therapy",
        "First-Line Therapy",
        "Preferred Selpercatinib or Pralsetinib",
        "Progression",
        "Subsequent Therapy",
        "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N1 nodes positive, M0",
        "Operable",
        "Surgical resectionl + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm and pN0",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Recurrence score 16–25",
        "Adjuvant endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Adjuvant systemic therapy (BINV-16) + WBRT",
        "HR-negative/ HER2-positive",
        "ypT0N0 or pCR",
        "Complete up to 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N0–1",
        "Initial Treatment (NSCL-12)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-positive",
        "BINV-9",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor ≤0.5 cm",
        "pN1mi Consider adjuvant chemotherapy with trastuzumab"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and Prior endocrine therapy within 1 y",
        "Postmenopausal",
        "Systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
        "Alternate systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Trachea/carina or mediastinum",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Systemic therapy or Concurrent chemoradiation",
        "Surgical reevaluation including chest CT ± PET/CT",
        "Surgery",
        "Margins positive (R1, R2)",
        "Resection and/or RT boost",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
        "Yes to all",
        "Consider no further axillary surgery"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 positive",
        "Definitive concurrent chemoradiationm,s (category 1)",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 3–4",
        "Best supportive care: NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive",
        "NTRK1/2/3 gene fusion",
        "NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances: Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Larotrectinib or Entrectinib or Repotrectinib",
        "Progression",
        "Repotrectinib (if not previously given) or Systemic Therapy, Subsequent (NSCL-K 4 of 5)",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Postmenopausal",
        "pT1-3 AND pN0 or pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN2/pN3 (≥4 ipsilateral metastases >2 mm)",
        "Adjuvant chemotherapy followed by endocrine therapy (category 1)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "erlotinib + ramucirumab or erlotinib + bevacizumab or dacomitinib or afatinib or erlotinib or gefitinib",
        "Progression Subsequent Therapy (NSCL-23)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-negative/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively) and/or Adjuvant capecitabine (6–8 cycles) and/or Adjuvant olaparib for 1 year if germline BRCA1/2 mutation (category 1)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-positive",
        "BINV-9",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor 0.6–1.0 cm",
        "Consider adjuvant chemotherapy with trastuzumab"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
        "No",
        "ALND level I/II"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
        "No",
        "ALND level I/II"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Disease outside of chest",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances: Crizotinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N0–1",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-positive",
        "BINV-5",
        "Ductal/NST • Lobular • Mixed • Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pNmi (≤2 mm axillary node metastasis)",
        "Tumor 0.6–1.0 cm",
        "Adjuvant endocrine therapy or Adjuvant chemotherapy with trastuzumab and endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Preferred: Osimertinib (category 1)",
        "Progression: Subsequent Therapy (NSCL-22)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "H&P (include performance status + weight loss)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
        "No",
        "ALND level I/II"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Other Recommended: Erlotinib or Gefitinib or Dacomitinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-positive",
        "BINV-9",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor ≤0.5 cm",
        "pN1mi Consider adjuvant chemotherapy with trastuzumab"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by alectinib (preferred) or brigatinib (preferred) or lorlatinib (preferred) or ceritinib or crizotinib",
        "Progression",
        "Subsequent Therapy (NSCL-28)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R1",
        "Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Multiple lung cancers",
        "Treatment (NSCL-12)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N0–1",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Contralateral mediastinal node negative",
        "Ipsilateral mediastinal node positive (T4, N2)",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Premenopausal",
        "Selective ER modulators",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and Prior endocrine therapy within 1 y",
        "Premenopausal",
        "Ovarian ablation or suppression + systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
        "Alternate systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by erlotinib or gefitinib or dacomitinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances: Crizotinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by afatinib (preferred) or osimertinib (preferred) or erlotinib or gefitinib or dacomitinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Disease outside of chest",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN not identified",
        "ALND level I/II"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Unresectable disease",
        "Treatment (NSCL-7)",
        "Stage IIIA (T4, N0–1) unresectable",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1) or Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N2–3",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered prior to first-line systemic therapy",
        "FIRST-LINE THERAPY",
        "Other Recommended: Systemic Therapy for Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Dabrafenib + trametinib or Encorafenib + binimetinib",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Postmenopausal",
        "pT1-3 AND pN0 or pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm or pN1mi (≥2 mm axillary node metastases) or pN1 (1–3 positive nodes)",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Recurrence score <26",
        "Adjuvant endocrine therapy (category 1)",
        "Follow-Up (BINV-17)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "Progression",
        "Systemic: Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Preferred Capmatinib or Tepotinib",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by selpercatinib (preferred), pralsetinib (preferred), cabozantinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "For tools to aid in the optimal assessment and management of NSCLC in older adults, see the NCCN Guidelines for Older Adult Oncology"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R2",
        "Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Progression",
        "PS 0–2",
        "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
        "Systemic therapy, Progression (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm and pN0",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Recurrence score ≥26",
        "Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Preferred: Osimertinib (category 1)",
        "Progression: Subsequent Therapy (NSCL-22)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "No apparent progression",
        "Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Incidental finding of nodule suspicious for lung cancer",
        "Multidisciplinary evaluation, Smoking cessation counseling",
        "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
        "Solid nodules Follow-up (DIAG-2)",
        "Incidental finding: solid nodule(s) on chest CT",
        "High risk",
        "6–8 mm CT at 6–12 mo",
        "Stable Repeat CT at 18–24 mo"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by osimertinib (preferred) or amivantamab-vmjw + lazertinib",
        "Progression: Subsequent Therapy (NSCL-22)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Superior sulcus tumor",
        "Treatment (NSCL-6)",
        "Superior sulcus tumor (T4 extension, N0–1)",
        "Possibly resectable",
        "Preoperative concurrent chemoradiation",
        "Surgical reevaluation including chest CT with or without contrast ± FDG-PET/CT",
        "Unresectable",
        "Complete definitive chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 3–4",
        "Best supportive care: NCCN Guidelines for Palliative Care"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "cT3, cN0, and ypN0: Consider RT to the chest wall + comprehensive RNI with inclusion of any portion of the undissected axilla at risk."
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
        "No",
        "ALND level I/II"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered prior to first-line systemic therapy",
        "First-Line Therapy",
        "Useful in Certain Circumstances Cabozantinib",
        "Progression",
        "Subsequent Therapy",
        "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Progression",
        "PS 0–2",
        "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
        "Systemic therapy, Progression (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Operable",
        "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R2",
        "Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-negative",
        "BINV-10",
        "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor 0.6–1.0 cm",
        "Consider adjuvant chemotherapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Disease outside of chest",
        "Systemic therapy for metastatic disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IVA (M1a) (pleural or pericardial effusion)",
        "Pretreatment Evaluation (NSCL-14)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Postmenopausal",
        "Systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
        "Alternate systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and PR-negative; HER2-positive",
        "BINV-26",
        "Systemic therapy + HER2-targeted therapy",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression",
        "Alternate systemic therapy + HER2-targeted therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further HER2-targeted therapy and continue supportive care (NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
        "Yes to all",
        "Consider no further axillary surgery"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
        "Yes to all",
        "Consider no further axillary surgery"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered prior to first-line systemic therapy",
        "Preferred Alectinibr (category 1) or Brigatinibr (category 1) or Lorlatinibr (category 1)",
        "Progression",
        "Subsequent Therapy (NSCL-28)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Preferred: Osimertinib",
        "Progression",
        "Subsequent Therapy (NSCL-22)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Micrometastases seen in SLN",
        "No further axillary surgery"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R1",
        "Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 positive",
        "Definitive concurrent chemoradiationm,s (category 1)",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Postmenopausal",
        "Systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
        "Alternate systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Progression",
        "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
        "Systemic therapy, Progression (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Unresectable disease",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 3–4",
        "Best supportive care: NCCN Guidelines for Palliative Care"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-negative/ HER2-positive",
        "ypT0N0 or pCR",
        "Complete up to 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 positive",
        "Definitive concurrent chemoradiationm,s (category 1)",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "No response to preoperative systemic therapy and/or tumor remains inoperable",
        "Consider additional systemic therapy and/or preoperative radiation",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "Smoking cessation advice, counseling, and pharmacotherapy"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Pretreatment Evaluation (NSCL-8)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "No response to preoperative systemic therapy and/or tumor remains inoperable",
        "Consider additional systemic therapy and/or preoperative radiation",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-positive/ HER2-positive",
        "ypT0N0 or pCR",
        "Endocrine therapy (category 1) + complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Operable",
        "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy (NSCL-K 3 of 5)",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN1mi (≤2 mm axillary node metastasis) or pN1 (1–3 positive nodes)",
        "Assess to determine if candidate for chemotherapy",
        "If candidate for chemotherapy consider gene expression assay to assess prognosis",
        "Adjuvant endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and Prior endocrine therapy within 1 y",
        "Postmenopausal",
        "Systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
        "Alternate systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Postmenopausal",
        "pT1-3 AND pN0 or pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN2/pN3 (≥4 ipsilateral metastases >2 mm)",
        "Adjuvant chemotherapy followed by endocrine therapy (category 1)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Disease outside of chest",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Operable",
        "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by afatinib (preferred) or osimertinib (preferred) or erlotinib or gefitinib or dacomitinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IIIB (T1–2, N3); Stage IIIC (T3, N3)",
        "Pretreatment Evaluation (NSCL-13)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Workup • History and physical exam • Imaging: ▸ Diagnostic bilateral mammogram ▸ Ultrasound as necessary ▸ Breast MRI (optional), with special consideration for mammographically occult tumors • Pathology review • Determination of tumor estrogen/ progesterone receptor (ER/PR) status and HER2 status • Genetic counseling and testing if patient is at risk for hereditary breast cancer, has triple-negative breast cancer (TNBC) (at any age), or is a candidate for adjuvant olaparib • Address fertility and sexual health concerns as appropriate • Pregnancy test in all patients of childbearing potential (If pregnant, see PREG-1) • Assess for distress • Consider additional imaging studies only in the presence of signs and symptoms of metastatic disease and for patients who are clinically high risk (BINV-18)",
        "If indicated: • Chest x-ray (with abdominal shielding) • Abdominal ultrasound to assess liver metastases • Consider non-contrast MRI of spine if indicated to assess for bone metastases",
        "If pregnant with confirmed breast cancer; No distant metastases on staging",
        "Second trimester/ Early third trimester",
        "Preoperative chemotherapy, mastectomy, or BCS + axillary staging",
        "± RT postpartum ± Adjuvant endocrine therapy postpartum"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-negative/ HER2-positive",
        "ypT0N0 or pCR",
        "Complete up to 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive"
    ],
    [
        "Clinical suspicion of Paget disease",
        "Clinical breast exam, Diagnostic bilateral mammogram, ultrasound as necessary",
        "Examination or imaging positive for breast lesion",
        "PAGET-2"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered prior to first-line systemic therapy",
        "FIRST-LINE THERAPY",
        "Preferred: Dabrafenib + trametinib or Encorafenib + binimetinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 3–4",
        "Best supportive care: NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N0–1",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IVA (M1a) (pleural or pericardial effusion)",
        "Pretreatment Evaluation (NSCL-14)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Definitive concurrent chemoradiationm,s (category 1) or Systemic",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive",
        "NTRK1/2/3 gene fusion",
        "NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances: Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Larotrectinib or Entrectinib or Repotrectinib",
        "Progression",
        "Repotrectinib (if not previously given) or Systemic Therapy, Subsequent (NSCL-K 4 of 5)",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN not identified",
        "ALND level I/II"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Disease outside of chest",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-negative/ HER2-positive",
        "ypT0N0 or pCR",
        "Complete up to 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Operable",
        "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Chest wall",
        "Treatment (NSCL-7)",
        "Stage IIIA (T4, N0–1) unresectable",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1) or Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R2",
        "Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "Integrate palliative care"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive",
        "NTRK1/2/3 gene fusion",
        "NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy",
        "Preferred: Larotrectinibrr or Entrectinibrr or Repotrectinibrr",
        "Progression",
        "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive",
        "ROS1 rearrangement",
        "ROS1 rearrangement discovered prior to first-line systemic therapy",
        "Preferred Entrectinib or Crizotinib or Repotrectinib or Other Recommended Ceritinib",
        "Progression",
        "Subsequent Therapy (NSCL-31)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN1mi (≤2 mm axillary node metastasis) or pN1 (1–3 positive nodes)",
        "Assess to determine if candidate for chemotherapy",
        "If candidate for chemotherapy consider gene expression assay to assess prognosis",
        "Adjuvant endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-negative/ HER2-negative",
        "ypT0N0 or pCR",
        "For high-risk. Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN negative",
        "No further axillary surgery (category 1)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R2",
        "Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN not identified",
        "ALND level I/II"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-positive/ HER2-negative",
        "ypT0N0 or pCR",
        "Adjuvant endocrine therapy (category 1)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Progression",
        "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
        "Systemic therapy, Progression (NSCL-K 4 of 5)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Superior sulcus tumor",
        "Treatment (NSCL-6)",
        "Superior sulcus tumor (T4 extension, N0–1)",
        "Possibly resectable",
        "Preoperative concurrent chemoradiation",
        "Surgical reevaluation including chest CT with or without contrast ± FDG-PET/CT",
        "Unresectable",
        "Complete definitive chemoradiation",
        "Durvalumab (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Progression",
        "Preferred: Fam-trastuzumab deruxtecan-nxki or Other Recommended: Ado-trastuzumab emtansine",
        "Progression",
        "PS 3–4",
        "Best supportive care: NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Stage IIIA (T4, N0–1)",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Systemic therapy or Concurrent chemoradiation",
        "Surgical reevaluation including chest CT ± PET/CT",
        "Surgery",
        "Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Incidental finding of nodule suspicious for lung cancer",
        "Multidisciplinary evaluation, Smoking cessation counseling",
        "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
        "Solid nodules Follow-up (DIAG-2)",
        "Incidental finding: solid nodule(s) on chest CT",
        "Low risk",
        "6–8 mm CT at 6–12 mo",
        "Stable Consider CT at 18–24 mo"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T2a–3, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if plannedp",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R2",
        "Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and Prior endocrine therapy within 1 y",
        "Premenopausal",
        "Ovarian ablation or suppression + systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R2",
        "Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by selpercatinib (preferred), pralsetinib (preferred), cabozantinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R1",
        "Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Trachea/carina or mediastinum",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive",
        "EGFR exon 20 insertion mutation",
        "Systemic therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Progression",
        "Amivantamab-vmjw",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)",
        "Definitive therapy for thoracic disease feasible",
        "Consider systemic therapy and restaging to confirm non-progression or Proceed to definitive therapy",
        "T1–3, N0",
        "Pathologic mediastinal nodal evaluation and Surgical resection or SABR"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by osimertinib (preferred)",
        "Progression",
        "Subsequent Therapy (NSCL-22)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy positive",
        "Consider preoperative chemotherapy",
        "No preoperative chemotherapy",
        "ALND level I/II"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and Prior endocrine therapy within 1 y",
        "Postmenopausal",
        "Systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T2a–3, N0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably SABR",
        "Consider adjuvant chemotherapyp for high-risk stage II",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N0–1",
        "Initial Treatment (NSCL-12)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by selpercatinib (preferred), pralsetinib (preferred), cabozantinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Other Recommended: Erlotinib or Gefitinib or Dacomitinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
        "ER-positive and/or PR-positive or ER-negative and PR-negative",
        "Favorable Histologies (BINV-11)",
        "Pure tubular • Pure mucinous • Pure cribriform",
        "ER-positive and/or PR-positive, HER2-negative",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "1–2.9 cm",
        "Consider adjuvant endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T2a–3, N0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably SABR",
        "Consider adjuvant chemotherapyp for high-risk stage II",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Premenopausal",
        "Ovarian ablation or suppression + systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "No apparent progression",
        "Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Premenopausal",
        "Selective ER modulators",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
        "Alternate systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R1",
        "Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Adjuvant systemic therapy (BINV-16) + WBRT",
        "HR-positive/ HER2-negative",
        "ypT0N0 or pCR",
        "Adjuvant endocrine therapy (category 1)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Workup • History and physical exam • Imaging: ▸ Diagnostic bilateral mammogram ▸ Ultrasound as necessary ▸ Breast MRI (optional), with special consideration for mammographically occult tumors • Pathology review • Determination of tumor estrogen/ progesterone receptor (ER/PR) status and HER2 status • Genetic counseling and testing if patient is at risk for hereditary breast cancer, has triple-negative breast cancer (TNBC) (at any age), or is a candidate for adjuvant olaparib • Address fertility and sexual health concerns as appropriate • Pregnancy test in all patients of childbearing potential (If pregnant, see PREG-1) • Assess for distress • Consider additional imaging studies only in the presence of signs and symptoms of metastatic disease and for patients who are clinically high risk (BINV-18)",
        "If indicated: • Chest x-ray (with abdominal shielding) • Abdominal ultrasound to assess liver metastases • Consider non-contrast MRI of spine if indicated to assess for bone metastases",
        "If pregnant with confirmed breast cancer; No distant metastases on staging",
        "Late third trimester",
        "Mastectomy or BCS + axillary staging",
        "Adjuvant chemotherapy ± RT postpartum ± Adjuvant endocrine therapy postpartum"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Clinical suspicion of Paget disease",
        "Clinical breast exam, Diagnostic bilateral mammogram, ultrasound as necessary",
        "Examination and imaging negative for breast lesion",
        "Examination or imaging positive for breast lesion",
        "Core biopsy of breast lesion and full-thickness skin biopsy of involved NAC",
        "Breast invasive cancer and NAC Paget",
        "See NCCN Guidelines for Invasive Breast Cancer (BINV-1)",
        "Appropriate systemic adjuvant therapy as clinically indicated, See NCCN Guidelines for DCIS or Invasive Breast Cancer"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T2a–3, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if plannedp",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Useful in Certain Circumstances Crizotinib",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and PR-negative; HER2-negative",
        "BINV-27",
        "Systemic therapy",
        "Continue therapy until progression or unacceptable toxicity",
        "Alternative systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and continue supportive care (NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "Any cN0, ypN0: If axilla was assessed by SLNB or axillary node dissection"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above",
        "PD-L1 POSITIVE (≥1%)",
        "PS 0–2",
        "Biomarker-directed therapy (NSCL-J 2 of 6)",
        "Response or stable disease",
        "Continuation maintenance"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Disease outside of chest",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by osimertinib (preferred) or amivantamab-vmjw + lazertinib",
        "Progression: Subsequent Therapy (NSCL-22)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Superior sulcus tumor",
        "Treatment (NSCL-6)",
        "Superior sulcus tumor (T4 extension, N0–1)",
        "Possibly resectable",
        "Preoperative concurrent chemoradiation",
        "Surgical reevaluation including chest CT with or without contrast ± FDG-PET/CT",
        "Unresectable",
        "Complete definitive chemoradiation",
        "Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by erlotinib or gefitinib or dacomitinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered prior to first-line systemic therapy",
        "Other Recommended Ceritinibr (category 1)",
        "Progression",
        "Subsequent Therapy (NSCL-28)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Progression",
        "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
        "Systemic therapy, Progression (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N1 nodes positive, M0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeonI and those who decline surgery after thoracic surgical consultation",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1 stage III; category 2A stage II) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1 stage III; category 2A stage II)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy (NSCL-K 3 of 5)",
        "Progression",
        "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
        "Systemic therapy, Progression (NSCL-K 4 of 5)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT0,cN+,M0",
        "See NCCN Guidelines for Occult Primary"
    ],
    [
        "Incidental finding of nodule suspicious for lung cancer",
        "Multidisciplinary evaluation, Smoking cessation counseling",
        "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
        "Subsolid nodules Follow-up (DIAG-3)",
        "Incidental finding: subsolid nodule(s) on chest CT",
        "Multiple subsolid nodules",
        "≥6 mm • CT at 3–6 mo • Subsequent management based on most suspicious nodule(s)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Adjuvant systemic therapy (BINV-16) + WBRT",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)",
        "Definitive therapy for thoracic disease feasible",
        "Consider systemic therapy and restaging to confirm non-progression or Proceed to definitive therapy",
        "T1–3, N0",
        "Pathologic mediastinal nodal evaluation and Surgical resection or SABR"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Preferred: Afatinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Incidental finding of nodule suspicious for lung cancer",
        "Multidisciplinary evaluation, Smoking cessation counseling",
        "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
        "Subsolid nodules Follow-up (DIAG-3)",
        "Incidental finding: subsolid nodule(s) on chest CT",
        "Solitary part-solid nodules",
        "≥6 mm • CT at 3–6 mo to confirm no growth or change in solid component, then annual CT for 5 y • If solid component ≥6 mm, consider PET/CT or biopsy"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Definitive concurrent chemoradiationm,s (category 1) or Systemic",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N2–3",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Chest wall",
        "Treatment (NSCL-7)",
        "Stage IIIA (T4, N0–1) unresectable",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1) or Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by dabrafenib + trametinib (preferred) or encorafenib + binimetinib (preferred)",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-negative",
        "BINV-10",
        "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor ≤0.5 cm",
        "pN0",
        "No adjuvant therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy (NSCL-K 3 of 5)",
        "Progression",
        "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
        "Systemic therapy, Progression (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Contralateral mediastinal node negative",
        "Ipsilateral mediastinal node negative (T4, N0–1)",
        "Treatment for Stage IIIA (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins positive",
        "R1",
        "Resection + chemotherapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "No apparent progression",
        "Surgery",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances Crizotinibb (category 1)",
        "Progression",
        "Subsequent Therapy (NSCL-29)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive",
        "EGFR exon 20 insertion mutation",
        "Systemic therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy",
        "Progression",
        "Amivantamab-vmjw",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "Integrate palliative care"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy possible",
        "Parenchymal sparing resection (preferred), or Radiation or Image-guided thermal ablation (IGTA)",
        "Surveillance",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "Any ypN+: RT is indicated to the chest wall + comprehensive RNI with inclusion of any portion of the undissected axilla at risk."
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Chest wall",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Systemic therapy or Concurrent chemoradiation",
        "Surgical reevaluation including chest CT ± PET/CT",
        "Surgery",
        "Margins positive (R1, R2)",
        "Resection and/or RT boost",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by osimertinib (preferred) or amivantamab-vmjw + lazertinib",
        "Progression: Subsequent Therapy (NSCL-22)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "No response to preoperative systemic therapy and/or tumor remains inoperable",
        "Consider additional systemic therapy and/or preoperative radiation",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-negative/ HER2-positive",
        "ypT0N0 or pCR",
        "Complete up to 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Stage IIIA (T4, N0–1)",
        "Treatment (NSCL-7)",
        "Stage IIIA (T4, N0–1) unresectable",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1) or Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered prior to first-line systemic therapy",
        "Preferred Alectinibr (category 1) or Brigatinibr (category 1) or Lorlatinibr (category 1)",
        "Progression",
        "Subsequent Therapy (NSCL-28)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Other Recommended: Osimertinib + pemetrexed + (cisplatin or carboplatin) (nonsquamous) (category 1)",
        "Progression, Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Superior sulcus tumor",
        "Treatment (NSCL-6)",
        "Superior sulcus tumor (T4 extension, N0–1)",
        "Unresectable",
        "Definitive concurrent chemoradiation",
        "Durvalumab (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "cT4, any N: RT is indicated to the chest wall + comprehensive RNI with inclusion of any portion of the undissected axilla at risk."
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-negative",
        "BINV-10",
        "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor >1 cm",
        "Adjuvant chemotherapy (category 1)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N0–1",
        "Initial Treatment (NSCL-12)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 positive",
        "Definitive concurrent chemoradiationm,s (category 1)",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Trachea/carina or mediastinum",
        "Treatment (NSCL-7)",
        "Stage IIIA (T4, N0–1) unresectable",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1) or Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Operable",
        "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered prior to first-line systemic therapy",
        "FIRST-LINE THERAPY",
        "Useful in Certain Circumstances: Vemurafenib or dabrafenib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Clinical suspicion of Paget disease",
        "Clinical breast exam, Diagnostic bilateral mammogram, ultrasound as necessary",
        "Examination and imaging negative for breast lesion",
        "Examination or imaging positive for breast lesion",
        "Core biopsy of breast lesion and full-thickness skin biopsy of involved NAC",
        "Breast and NAC biopsy negative",
        "Clinical follow-up Re-biopsy if not healing",
        "Appropriate systemic adjuvant therapy as clinically indicated, See NCCN Guidelines for DCIS or Invasive Breast Cancer"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)",
        "Definitive therapy for thoracic disease not feasible",
        "Systemic Therapy for Metastatic Disease"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
        "No",
        "ALND level I/II"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N0–1",
        "Initial Treatment (NSCL-12)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
        "ER-positive and/or PR-positive or ER-negative and PR-negative",
        "Favorable Histologies (BINV-11)",
        "Adenoid cystic (conventional), secretory • Carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinomas",
        "ER-negative and PR-negative, HER2-negative",
        "Limited available data support local therapy only with consideration for systemic/targeted therapies only in pN+ disease",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-positive/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant endocrine therapy (category 1) + adjuvant olaparib if germline BRCA1/2 mutation CPS+EG score ≥3, and residual disease (category 1). Select patients may be eligible for adjuvant abemaciclib, see BINV-K for eligibility criteria."
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy (NSCL-K 3 of 5)",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Progression",
        "Preferred: Fam-trastuzumab deruxtecan-nxki or Other Recommended: Ado-trastuzumab emtansine",
        "Progression",
        "PS 3–4",
        "Best supportive care: NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N2–3",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by crizotinib",
        "Progression",
        "Subsequent Therapy (NSCL-29)"
    ],
    [
        "Incidental finding of nodule suspicious for lung cancer",
        "Multidisciplinary evaluation, Smoking cessation counseling",
        "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
        "Subsolid nodules Follow-up (DIAG-3)",
        "Incidental finding: subsolid nodule(s) on chest CT",
        "Solitary part-solid nodules",
        "<6 mm No routine follow-up"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "Progression",
        "Local: RT (if feasible) ± chemotherapy"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Other Recommended: Amivantamab-vmjw + lazertinib (category 1)",
        "Progression: Subsequent Therapy (NSCL-22)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Other Recommended: Amivantamab-vmjw + lazertinib (category 1)",
        "Progression: Subsequent Therapy (NSCL-22)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive",
        "NTRK1/2/3 gene fusion",
        "NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances: Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Larotrectinib or Entrectinib or Repotrectinib",
        "Progression",
        "Repotrectinib (if not previously given) or Systemic Therapy, Subsequent (NSCL-K 4 of 5)",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Trachea/carina or mediastinum",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins positive",
        "R1",
        "Resection + chemotherapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "No apparent progression",
        "Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered prior to first-line systemic therapy",
        "FIRST-LINE THERAPY",
        "Other Recommended: Systemic Therapy for Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Dabrafenib + trametinib or Encorafenib + binimetinib",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor ≤0.5 cm and pN0",
        "Consider adjuvant endocrine therapy (category 2B)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 positive",
        "Definitive concurrent chemoradiationm,s (category 1)",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Operable",
        "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered prior to first-line systemic therapy",
        "First-Line Therapy",
        "Useful in Certain Circumstances Cabozantinib",
        "Progression",
        "Subsequent Therapy",
        "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-positive",
        "BINV-5",
        "Ductal/NST • Lobular • Mixed • Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pNmi (≤2 mm axillary node metastasis)",
        "Tumor >1 cm",
        "Adjuvant chemotherapy with trastuzumab (category 1) and endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by crizotinib",
        "Progression",
        "Subsequent Therapy (NSCL-29)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R1",
        "Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Chest wall",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Superior sulcus tumor",
        "Treatment (NSCL-6)",
        "Superior sulcus tumor (T4 extension, N0–1)",
        "Unresectable",
        "Definitive concurrent chemoradiation",
        "Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
        "ER-positive and/or PR-positive or ER-negative and PR-negative",
        "Favorable Histologies (BINV-11)",
        "Adenoid cystic (conventional), secretory • Carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinomas",
        "ER-negative and PR-negative, HER2-negative",
        "Limited available data support local therapy only with consideration for systemic/targeted therapies only in pN+ disease",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Unresectable disease",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins positive",
        "R2",
        "Resection + chemotherapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-negative/ HER2-negative",
        "ypT0N0 or pCR",
        "For high-risk. Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Preferred: Osimertinib (category 1)",
        "Progression: Subsequent Therapy (NSCL-22)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy positive",
        "Consider preoperative chemotherapy",
        "Yes, preoperative chemotherapy",
        "cN+ converts to clinically node negative",
        "SLNB (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Premenopausal",
        "Ovarian ablation or suppression + systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered prior to first-line systemic therapy",
        "First-Line Therapy",
        "Other Recommended: Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Progression",
        "Preferred: Selpercatinib or Pralsetinib; Useful in Certain Circumstances: Cabozantinib",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive",
        "ROS1 rearrangement",
        "ROS1 rearrangement discovered prior to first-line systemic therapy",
        "Preferred Entrectinib or Crizotinib or Repotrectinib or Other Recommended Ceritinib",
        "Progression",
        "Subsequent Therapy (NSCL-31)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "CT chest and upper abdomen with contrast, including adrenals"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 positive",
        "Definitive concurrent chemoradiationm,s (category 1)",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Postmenopausal",
        "Systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered prior to first-line systemic therapy",
        "First-Line Therapy",
        "Other Recommended: Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Progression",
        "Preferred: Selpercatinib or Pralsetinib; Useful in Certain Circumstances: Cabozantinib",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Incidental finding of nodule suspicious for lung cancer",
        "Multidisciplinary evaluation, Smoking cessation counseling",
        "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
        "Solid nodules Follow-up (DIAG-2)",
        "Incidental finding: solid nodule(s) on chest CT",
        "High risk",
        "< 6 mm CT at 12 mo (optional)",
        "Stable No routine follow-up"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Premenopausal",
        "Selective ER modulators",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "erlotinib + ramucirumab or erlotinib + bevacizumab or dacomitinib or afatinib or erlotinib or gefitinib",
        "Progression Subsequent Therapy (NSCL-23)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Micrometastases seen in SLN",
        "No further axillary surgery"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Incidental finding of nodule suspicious for lung cancer",
        "Multidisciplinary evaluation, Smoking cessation counseling",
        "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
        "Subsolid nodules Follow-up (DIAG-3)",
        "Incidental finding: subsolid nodule(s) on chest CT",
        "Solitary pure ground-glass nodules",
        "≥6 mm CT at 6–12 mo to confirm no growth or development of a solid component, then CT every 2 y until 5 y"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 positive",
        "Definitive concurrent chemoradiationm,s (category 1)",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered prior to first-line systemic therapy",
        "Preferred Alectinibr (category 1) or Brigatinibr (category 1) or Lorlatinibr (category 1)",
        "Progression",
        "Subsequent Therapy (NSCL-28)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Stage IIIA (T4, N0–1)",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Surgery (preferred)",
        "Margins positive",
        "R1",
        "Resection + chemotherapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Postmenopausal",
        "Systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "Visceral crisis",
        "Consider initial systemic therapy",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Adjuvant systemic therapy (BINV-16) + WBRT",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N1 nodes positive, M0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeonI and those who decline surgery after thoracic surgical consultation",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1 stage III; category 2A stage II) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1 stage III; category 2A stage II)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive",
        "EGFR exon 20 insertion mutation",
        "Amivantamab-vmjw + carboplatin/pemetrexed (nonsquamous) (category 1) (preferred)",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive",
        "ROS1 rearrangement",
        "ROS1 rearrangement discovered prior to first-line systemic therapy",
        "Preferred Entrectinib or Crizotinib or Repotrectinib or Other Recommended Ceritinib",
        "Progression",
        "Subsequent Therapy (NSCL-31)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Premenopausal",
        "Selective ER modulators",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive",
        "EGFR exon 20 insertion mutation",
        "Amivantamab-vmjw + carboplatin/pemetrexed (nonsquamous) (category 1) (preferred)",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Progression",
        "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
        "Systemic therapy, Progression (NSCL-K 4 of 5)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Disease outside of chest",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Clinical suspicion of Paget disease",
        "Clinical breast exam, Diagnostic bilateral mammogram, ultrasound as necessary",
        "Examination and imaging negative for breast lesion",
        "Examination and imaging negative for breast lesion",
        "Full-thickness skin biopsy of involved NAC",
        "NAC biopsy positive for Paget",
        "Consider breast MRI and tissue sampling",
        "Central lumpectomy including NAC with WBRT or Total mastectomy ± SLNB with or without breast reconstruction or Central lumpectomy including NAC ± SLNB without RT (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive",
        "ROS1 rearrangement",
        "ROS1 rearrangement discovered prior to first-line systemic therapy",
        "Preferred Entrectinib or Crizotinib or Repotrectinib or Other Recommended Ceritinib",
        "Progression",
        "Subsequent Therapy (NSCL-31)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T2a–3, N0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably SABR",
        "Consider adjuvant chemotherapyp for high-risk stage II",
        "Surveillance (NSCL-17)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN negative",
        "No further axillary surgery (category 1)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-positive",
        "BINV-24",
        "Systemic therapy + HER2-targeted therapy or Endocrine therapy ± HER2-targeted therapy (if premenopausal, consider ovarian ablation or suppression)",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression (BINV-25)",
        "Progression on first-line endocrine therapy ± HER2-targeted therapy",
        "Consider alternate endocrine therapy, if not endocrine refractory ± HER2-targeted therapy"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN positive",
        "Mastectomy",
        "Micrometastases seen in SLN",
        "No further axillary surgery"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Progression",
        "Preferred: Fam-trastuzumab deruxtecan-nxki or Other Recommended: Ado-trastuzumab emtansine",
        "Progression",
        "PS 3–4",
        "Best supportive care: NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "Progression",
        "Systemic: Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by osimertinib (preferred)",
        "Progression",
        "Subsequent Therapy (NSCL-22)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and Prior endocrine therapy within 1 y",
        "Postmenopausal",
        "Systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Postmenopausal",
        "pT1-3 AND pN0 or pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm or pN1mi (≥2 mm axillary node metastases) or pN1 (1–3 positive nodes)",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Recurrence score ≥26",
        "Adjuvant chemotherapy followed by endocrine therapy (category 1)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Preferred: Afatinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "No nodal disease",
        "Medically inoperable, high surgical risk as determined by thoracic surgeon, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably SABR",
        "Consider adjuvant chemotherapy for high-risk stage II",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T2a–3, N0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably SABR",
        "Consider adjuvant chemotherapyp for high-risk stage II",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered prior to first-line systemic therapy",
        "Other Recommended Ceritinibr (category 1)",
        "Progression",
        "Subsequent Therapy (NSCL-28)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "No response to preoperative systemic therapy and/or tumor remains inoperable",
        "Consider additional systemic therapy and/or preoperative radiation",
        "No response to preoperative systemic therapy and tumor is inoperable",
        "Individualize treatment"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "Visceral crisis",
        "Consider initial systemic therapy",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "No response to preoperative systemic therapy and/or tumor remains inoperable",
        "Consider additional systemic therapy and/or preoperative radiation",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "RET rearrangement positive",
        "RET rearrangement",
        "RET rearrangement discovered prior to first-line systemic therapy",
        "First-Line Therapy",
        "Preferred Selpercatinib or Pralsetinib",
        "Progression",
        "Subsequent Therapy",
        "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm and pN0",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Recurrence score ≤15",
        "Adjuvant endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-positive",
        "BINV-5",
        "Ductal/NST • Lobular • Mixed • Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pNmi (≤2 mm axillary node metastasis)",
        "Tumor ≤0.5 cm",
        "pN0",
        "Consider adjuvant endocrine therapy or Consider adjuvant chemotherapy with trastuzumab (category 2B) and endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "CBC, platelets"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 3–4",
        "Best supportive care: NCCN Guidelines for Palliative Care"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N1 nodes positive, M0",
        "Operable",
        "Surgical resectionl + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Postmenopausal",
        "pT1-3 AND pN0 or pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor ≤0.5 cm and pN0",
        "Consider adjuvant endocrine therapy (category 2B)",
        "Follow-Up (BINV-17)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances Crizotinibb (category 1)",
        "Progression",
        "Subsequent Therapy (NSCL-29)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive",
        "EGFR exon 20 insertion mutation",
        "Systemic therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy",
        "Progression",
        "Amivantamab-vmjw",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN0",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm and pN0",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Not done",
        "Adjuvant endocrine therapy ± ovarian suppression/ablation",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-positive",
        "BINV-24",
        "Systemic therapy + HER2-targeted therapy or Endocrine therapy ± HER2-targeted therapy (if premenopausal, consider ovarian ablation or suppression)",
        "Continue therapy until progression or unacceptable toxicity",
        "Progression (BINV-25)",
        "Progression on systemic therapy + HER2-targeted therapy",
        "Alternate systemic therapy + HER2-targeted therapy"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy possible",
        "Parenchymal sparing resection (preferred), or Radiation or Image-guided thermal ablation (IGTA)",
        "Surveillance",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and Prior endocrine therapy within 1 y",
        "Premenopausal",
        "Ovarian ablation or suppression + systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
        "Alternate systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Definitive concurrent chemoradiationm,s (category 1) or Systemic",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered prior to first-line systemic therapy",
        "FIRST-LINE THERAPY",
        "Useful in Certain Circumstances: Vemurafenib or dabrafenib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Disease outside of chest",
        "Systemic therapy for metastatic disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease present",
        "Add denosumab zoledronic acid, or pamidronate",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and Prior endocrine therapy within 1 y",
        "Postmenopausal",
        "Systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
        "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-negative/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively) and/or Adjuvant capecitabine (6–8 cycles) and/or Adjuvant olaparib for 1 year if germline BRCA1/2 mutation (category 1)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "CT chest and upper abdomen with contrast, including adrenals"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 3–4",
        "Best supportive care: NCCN Guidelines for Palliative Care"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Premenopausal",
        "Selective ER modulators",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
        "Alternate systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by erlotinib or gefitinib or dacomitinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Chest wall",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Systemic therapy or Concurrent chemoradiation",
        "Surgical reevaluation including chest CT ± PET/CT",
        "Surgery",
        "Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 0–2",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive",
        "NTRK1/2/3 gene fusion",
        "NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy",
        "Preferred: Larotrectinibrr or Entrectinibrr or Repotrectinibrr",
        "Progression",
        "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R1",
        "Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Pretreatment Evaluation (NSCL-8)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive",
        "EGFR exon 20 insertion mutation",
        "Systemic therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Response or stable disease",
        "Maintenance therapy",
        "Progression",
        "Amivantamab-vmjw",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN negative",
        "No further axillary surgery (category 1)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy positive",
        "Consider preoperative chemotherapy",
        "Yes, preoperative chemotherapy",
        "cN+ remains clinically positive",
        "ALND level I/II"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Trachea/carina or mediastinum",
        "Treatment (NSCL-7)",
        "Stage IIIA (T4, N0–1) unresectable",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1) or Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "No response to preoperative systemic therapy and/or tumor remains inoperable",
        "Consider additional systemic therapy and/or preoperative radiation",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-positive/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant endocrine therapy (category 1) + adjuvant olaparib if germline BRCA1/2 mutation CPS+EG score ≥3, and residual disease (category 1). Select patients may be eligible for adjuvant abemaciclib, see BINV-K for eligibility criteria."
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably SABR",
        "Surveillance (NSCL-17)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "Any ypN+: RT is indicated to the chest wall + comprehensive RNI with inclusion of any portion of the undissected axilla at risk."
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive",
        "BRAF V600E MUTATION",
        "BRAF V600E mutation discovered prior to first-line systemic therapy",
        "FIRST-LINE THERAPY",
        "Preferred: Dabrafenib + trametinib or Encorafenib + binimetinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R1",
        "Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Incidental finding of nodule suspicious for lung cancer",
        "Multidisciplinary evaluation, Smoking cessation counseling",
        "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
        "Solid nodules Follow-up (DIAG-2)",
        "Incidental finding: solid nodule(s) on chest CT",
        "High risk",
        "> 8 mm Consider CT at 3 mo, FDG-PET/CT, or biopsy"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances: Erlotinib + ramucirumab or Erlotinib + bevacizumab or Dacomitinib (category 1) or Afatinib (category 1) or Erlotinib (category 1) or Gefitinib (category 1)",
        "Progression: Subsequent Therapy (NSCL-23)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Superior sulcus tumor",
        "Treatment (NSCL-6)",
        "Superior sulcus tumor (T4 extension, N0–1)",
        "Possibly resectable",
        "Preoperative concurrent chemoradiation",
        "Surgical reevaluation including chest CT with or without contrast ± FDG-PET/CT",
        "Resectable",
        "Surgery + Adjuvant Systemic Therapy",
        "Surveillance"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Premenopausal",
        "pT1-3 AND pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pN2/pN3 (≥4 ipsilateral metastases >2 mm)",
        "Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation (category 1)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Premenopausal",
        "Ovarian ablation or suppression + systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IIIB (T4, N2); Stage IIIC (T4, N3)",
        "Pretreatment Evaluation (NSCL-14)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances: Erlotinib + ramucirumab or Erlotinib + bevacizumab or Dacomitinib (category 1) or Afatinib (category 1) or Erlotinib (category 1) or Gefitinib (category 1)",
        "Progression: Subsequent Therapy (NSCL-23)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive",
        "ERBB2 (HER2) mutation",
        "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
        "Tumor response evaluation",
        "Response or stable disease",
        "Progression",
        "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
        "Progression",
        "PS 3–4",
        "Best supportive care: NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Multiple lesions",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
        "ER-positive and/or PR-positive or ER-negative and PR-negative",
        "Favorable Histologies (BINV-11)",
        "Pure tubular • Pure mucinous • Pure cribriform",
        "ER-positive and/or PR-positive, HER2-negative",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "≥3 cm",
        "Adjuvant endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy positive",
        "Consider preoperative chemotherapy",
        "Yes, preoperative chemotherapy",
        "cN+ remains clinically positive",
        "ALND level I/II"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "Progression",
        "Systemic: Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Postmenopausal",
        "pT1-3 AND pN0 or pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor >0.5 cm or pN1mi (≥2 mm axillary node metastases) or pN1 (1–3 positive nodes)",
        "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
        "Not done",
        "Adjuvant chemotherapy followed by endocrine therapy (category 1) or Adjuvant endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Clinical suspicion of Paget disease",
        "Clinical breast exam, Diagnostic bilateral mammogram, ultrasound as necessary",
        "Examination and imaging negative for breast lesion",
        "Examination and imaging negative for breast lesion",
        "Full-thickness skin biopsy of involved NAC",
        "NAC biopsy negative for Paget",
        "Clinical follow-up Re-biopsy if not healing"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N1 nodes positive, M0",
        "Operable",
        "Surgical resectionl + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIA (T2b, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N0–1",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive",
        "EGFR exon 20 insertion mutation",
        "Systemic therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Progression",
        "Amivantamab-vmjw",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered prior to first-line systemic therapy",
        "Other Recommended Ceritinibr (category 1)",
        "Progression",
        "Subsequent Therapy (NSCL-28)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive",
        "ALK rearrangement",
        "ALK rearrangement discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances Crizotinibb (category 1)",
        "Progression",
        "Subsequent Therapy (NSCL-29)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ERBB2 (HER2) mutation positive"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IB (T2a, N0); Margins negative (R0)",
        "Observe or Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-positive/ HER2-positive",
        "ypT0N0 or pCR",
        "Endocrine therapy (category 1) + complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above",
        "PD-L1 POSITIVE (≥1%)",
        "PS 0–2",
        "Biomarker-directed therapy (NSCL-J 2 of 6)",
        "Progression",
        "Systemic Therapy (NSCL-K 1 of 5) or Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Other Recommended: Osimertinib + pemetrexed + (cisplatin or carboplatin) (nonsquamous) (category 1)",
        "Progression, Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ALK rearrangement positive"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Micrometastases seen in SLN",
        "No further axillary surgery"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Disease outside of chest",
        "Systemic therapy for metastatic disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N0–1",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R2; Resection + systemic therapy or Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered prior to first-line systemic therapy",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Useful in Certain Circumstances Crizotinib",
        "Progression",
        "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "erlotinib + ramucirumab or erlotinib + bevacizumab or dacomitinib or afatinib or erlotinib or gefitinib",
        "Progression Subsequent Therapy (NSCL-23)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "1–3 positive axillary nodes",
        "Strongly consider RT to chest wall + comprehensive RNI (including any portion of the undissected axilla at risk)."
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Brain",
        "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy positive",
        "Consider preoperative chemotherapy",
        "Yes, preoperative chemotherapy",
        "cN+ converts to clinically node negative",
        "SLNB (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Adjuvant systemic therapy (BINV-16) + WBRT",
        "Any cN0, ypN0: Adjuvant RT to whole breast ± boost to tumor bed"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
        "Yes to all",
        "No further axillary surgery"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Initial Evaluation",
        "CBC, platelets"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
        "Definitive RT, preferably SABR",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Clinical pathologic diagnosis of IBC",
        "History and physical exam by multidisciplinary team and obtain medical photography, CBC, Comprehensive metabolic panel, including LFTs and alkaline phosphatase, Pathology review, Determination of tumor ER/PR status and HER2 status, Fertility counseling if premenopausal, Genetic counseling if patient is at risk for hereditary breast cancer, Imaging: Bilateral diagnostic mammogram, ultrasound as necessary, Chest diagnostic CT ± contrast, Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast, Bone scan or FDG-PET/CT, Breast MRI (optional)",
        "Preoperative/Adjuvant Therapy Regimens (BINV-L)",
        "Response to preoperative therapy",
        "Response",
        "Total mastectomy + level I/II axillary dissection + RT to chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk ± delayed breast reconstruction",
        "Complete planned chemotherapy regimen course if not completed preoperatively plus endocrine treatment if ER-positive and/or PR-positive (sequential chemotherapy followed by endocrine therapy). Complete up to one year of HER2-targeted therapy if HER2-positive (category 1). May be administered concurrently with RT and with endocrine therapy if indicated."
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 3–4",
        "Systemic Therapy for Metastatic Disease (NSCL-19)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 20 insertion mutation positive"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Adjuvant systemic therapy (BINV-16) + WBRT",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 positive",
        "Definitive concurrent chemoradiationm,s (category 1)",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
        "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N0–1",
        "Initial Treatment (NSCL-12)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins positive",
        "R2",
        "Concurrent chemoradiation",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N0–1",
        "Initial Treatment (NSCL-12)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-negative and PR-negative",
        "HER2-positive",
        "BINV-9",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
        "Tumor >1 cm",
        "Adjuvant chemotherapy with trastuzumab (category 1)"
    ],
    [
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "RET rearrangement positive"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N3 nodes positive, M0",
        "Stage IIIB or Stage IIIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN negative",
        "No further axillary surgery (category 1)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-positive",
        "BINV-5",
        "Ductal/NST • Lobular • Mixed • Micropapillary",
        "pN+ (≥1 ipsilateral metastases >2 mm)",
        "Adjuvant chemotherapy with trastuzumab (category 1) and endocrine therapy or Adjuvant chemotherapy with trastuzumab + pertuzumab (category 1, preferred) and endocrine therapy",
        "Follow-Up (BINV-17)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IIIB (T4, N2); Stage IIIC (T4, N3)",
        "Pretreatment Evaluation (NSCL-14)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive",
        "KRAS G12C mutation",
        "Systemic therapy • PD-L1 ≥1% (NSCLC-37) • PD-L1 <1% (NSCLC-38)",
        "Tumor response evaluation",
        "Response or stable disease",
        "4–6 cycles (total)",
        "Tumor response evaluation",
        "Progression",
        "Sotorasib or Adagrasib",
        "Progression",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 0–2",
        "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Tumor response evaluation",
        "Progression",
        "PS 0–2",
        "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
        "Systemic therapy, Progression (NSCL-K 4 of 5)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
        "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Contralateral mediastinal node negative",
        "Ipsilateral mediastinal node positive (T4, N2)",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above",
        "PD-L1 POSITIVE (≥1%)",
        "PS 0–2",
        "Biomarker-directed therapy (NSCL-J 2 of 6)",
        "Response or stable disease",
        "Continuation maintenance"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "No prior RT",
        "Concurrent chemoradiation",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
        "HR-positive/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above",
        "PD-L1 POSITIVE (≥1%)",
        "PS 3–4",
        "Best supportive care (NCCN Guidelines for Palliative Care)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
        "Treatment",
        "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
        "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "No disease outside of chest",
        "Pathologic mediastinal lymph node evaluation",
        "N2–3",
        "Systemic therapy for metastatic disease (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)",
        "Definitive therapy for thoracic disease feasible",
        "Consider systemic therapy and restaging to confirm non-progression or Proceed to definitive therapy",
        "T1–3, N1",
        "Pathologic mediastinal nodal evaluation and Chemoradiation (preferred) or Surgical resection or Definitive RT",
        "Definitive local therapy for metastatic site if not already given",
        "Consider systemic therapy, if not already given"
    ],
    [
        "Stage IIA (T2b, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered prior to first-line systemic therapy",
        "Useful in Certain Circumstances: Erlotinib + ramucirumab or Erlotinib + bevacizumab or Dacomitinib (category 1) or Afatinib (category 1) or Erlotinib (category 1) or Gefitinib (category 1)",
        "Progression: Subsequent Therapy (NSCL-23)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Clinical suspicion of Paget disease",
        "Clinical breast exam, Diagnostic bilateral mammogram, ultrasound as necessary",
        "Examination and imaging negative for breast lesion",
        "Examination or imaging positive for breast lesion",
        "Core biopsy of breast lesion and full-thickness skin biopsy of involved NAC",
        "Breast negative for cancer and positive NAC Paget",
        "Consider breast MRI and tissue sampling",
        "Central lumpectomy including NAC with WBRT or Total mastectomy ± SLNB with or without breast reconstruction or Central lumpectomy including NAC ± SLNB without RT (category 2B)",
        "Appropriate systemic adjuvant therapy as clinically indicated, See NCCN Guidelines for DCIS or Invasive Breast Cancer"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive",
        "EGFR exon 19 deletion or exon 21 L858R mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "erlotinib + ramucirumab or erlotinib + bevacizumab or dacomitinib or afatinib or erlotinib or gefitinib",
        "Progression Subsequent Therapy (NSCL-23)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Unresectable disease",
        "Treatment (NSCL-7)",
        "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
        "Systemic therapy or Concurrent chemoradiation",
        "Surgical reevaluation including chest CT ± PET/CT",
        "Surgery",
        "Margins positive (R1, R2)",
        "Resection and/or RT boost",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "BRAF V600E mutation positive"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Negative",
        "Treatment according to TNM stage"
    ],
    [
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "N3 negative",
        "Initial treatment for stage I–IIIA (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "No apparent progression",
        "Surgery",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "EGFR exon 19 deletion or exon 21 L858R mutation positive"
    ],
    [
        "Clinical suspicion of Paget disease",
        "Clinical breast exam, Diagnostic bilateral mammogram, ultrasound as necessary",
        "Examination and imaging negative for breast lesion",
        "Examination or imaging positive for breast lesion",
        "Core biopsy of breast lesion and full-thickness skin biopsy of involved NAC",
        "Breast DCIS and NAC Paget",
        "See NCCN Guidelines for Noninvasive Breast Cancer for DCIS (DCIS-1)",
        "Appropriate systemic adjuvant therapy as clinically indicated, See NCCN Guidelines for DCIS or Invasive Breast Cancer"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Negative mediastinal nodes",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IA (T1abc, N0); Margins negative (R0)",
        "Observe",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
        "Sequential chemotherapy and consider RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Disseminated metastases",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN negative",
        "No further axillary surgery (category 1)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Resectable recurrence",
        "Resection (preferred); External-beam RT or SABR",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Severe hemoptysis",
        "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "ROS1 rearrangement positive",
        "ROS1 rearrangement",
        "ROS1 rearrangement discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by entrectinibr (preferred), crizotinib (preferred), repotrectinibr (preferred), or ceritinib",
        "Progression",
        "Subsequent Therapy (NSCL-31)"
    ],
    [
        "Multiple lung cancers (suspected or confirmed) (N0–1)",
        "Multidisciplinary evaluation",
        "Dominant nodule with evidence of growth",
        "Definitive local therapy not possible",
        "Palliative chemotherapy ± local palliative therapy or Observe",
        "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results (NSCL-20)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N1 nodes positive, M0",
        "Medically inoperable, high surgical risk as determined by thoracic surgeonI and those who decline surgery after thoracic surgical consultation",
        "Definitive concurrent chemoradiation (category 1)",
        "Durvalumab (category 1 stage III; category 2A stage II) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1 stage III; category 2A stage II)",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
        "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
        "Metastatic disease",
        "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "EGFR S768I, L861Q, and/or G719X mutation positive",
        "EGFR S768I, L861Q, and/or G719X mutations",
        "EGFR mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by afatinib (preferred) or osimertinib (preferred) or erlotinib or gefitinib or dacomitinib",
        "Progression",
        "Subsequent Therapy (NSCL-23)"
    ],
    [
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
        "Pathologic Diagnosis of NSCLC",
        "Clinical Stage",
        "Stage IVB (M1c) disseminated metastases",
        "Systemic Therapy (NSCL-19)"
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
        "Treatment",
        "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
        "Surgery after preoperative systemic therapy, if planned",
        "N2",
        "Margins negative (R0)",
        "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "METex14 skipping mutation positive",
        "METex14 skipping mutation",
        "METex14 skipping mutation discovered during first-line systemic therapy",
        "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by capmatinib (preferred) or tepotinib (preferred) or crizotinib",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above",
        "PD-L1 <1%",
        "INITIAL SYSTEMIC THERAPY",
        "PS 3–4",
        "Best supportive care NCCN Guidelines for Palliative Care"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R2; Concurrent chemoradiation",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Endobronchial obstruction",
        "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "Evidence of disseminated disease",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IA (peripheral T1abc, N0)",
        "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
        "Positive mediastinal nodes",
        "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "N1 or N2 nodes positive, M0",
        "Treatment (NSCL-10)",
        "Mediastinal Biopsy Findings",
        "T1–3, N2 nodes positive, M0",
        "Systemic therapy ± RT",
        "Progression",
        "Systemic: Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Diffuse brain metastases",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "NTRK1/2/3 gene fusion positive",
        "NTRK1/2/3 gene fusion",
        "NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy",
        "Preferred: Larotrectinibrr or Entrectinibrr or Repotrectinibrr",
        "Progression",
        "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "Progression",
        "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
        "Preoperative systemic therapy see BINV-M 1",
        "No response to preoperative systemic therapy and/or tumor remains inoperable",
        "Consider additional systemic therapy and/or preoperative radiation",
        "Response to preoperative systemic therapy and tumor is operable",
        "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
        "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
        "HR-negative/ HER2-positive",
        "ypT1–4,N0 or ypN≥1",
        "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
    ],
    [
        "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
        "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
        "N1 or N2 disease",
        "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
        "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
        "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
        "Extrathoracic metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "PS 0–2",
        "Limited progression confirmed",
        "Other site",
        "Treatment of Thoracic Disease (NSCL-16)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Not considering preoperative systemic therapy",
        "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
        "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
        "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
        "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
        "ER-positive and/or PR-positive",
        "HER2-negative",
        "Postmenopausal",
        "pT1-3 AND pN0 or pN+",
        "Ductal/NST, Lobular, Mixed, Micropapillary",
        "Tumor ≤0.5 cm and pN0",
        "Consider adjuvant endocrine therapy (category 2B)",
        "Follow-Up (BINV-17)"
    ],
    [
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above",
        "PD-L1 POSITIVE (≥1%)",
        "PS 0–2",
        "Biomarker-directed therapy (NSCL-J 2 of 6)",
        "Response or stable disease",
        "Continuation maintenance"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Nodes negative",
        "Treatment (NSCL-9)",
        "T1, N0",
        "Operable",
        "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
        "Adjuvant Treatment (NSCL-4)",
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
        "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
        "FNA or core biopsy negative",
        "SLN mapping and excision",
        "SLN positive",
        "Breast-conserving surgery",
        "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
        "Yes to all",
        "No further axillary surgery"
    ],
    [
        "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
        "R1; Chemoradiation (sequential or concurrent)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Locoregional recurrence",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Limited metastases",
        "Stage IV, M1b (NSCL-15)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS not possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
        "SLN mapping and excision",
        "SLN negative",
        "No further axillary surgery (category 1)"
    ],
    [
        "Stage IVA, M1b",
        "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "PD-L1 ≥1% and negative for actionable molecular biomarkers above",
        "PD-L1 POSITIVE (≥1%)",
        "PS 3–4",
        "Best supportive care (NCCN Guidelines for Palliative Care)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Localized symptoms",
        "Palliative external-beam RT",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Squamous cell carcinoma",
        "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
        "Testing Results",
        "PD-L1 <1% and negative for actionable molecular biomarkers above"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
        "Adjuvant systemic therapy (BINV-16) + WBRT",
        "HR-negative/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively) and/or Adjuvant capecitabine (6–8 cycles) and/or Adjuvant olaparib for 1 year if germline BRCA1/2 mutation (category 1)"
    ],
    [
        "Stage IVA, M1a: pleural or pericardial effusion",
        "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
        "Positive",
        "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
        "Advanced or metastatic disease",
        "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
        "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
        "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
        "Testing Results",
        "KRAS G12C mutation positive"
    ],
    [
        "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
        "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
        "Metastatic disease",
        "Treatment for Metastasis limited sites or distant disease",
        "Locoregional recurrence or symptomatic local disease",
        "Mediastinal lymph node recurrence",
        "Prior RT",
        "Systemic therapy (NSCL-19)",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IB (T2a, N0); Margins positive (R1, R2)",
        "Resection (preferred) ± systemic therapy or RT",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Locoregional recurrence or symptomatic local disease",
        "Superior vena cava (SVC) obstruction",
        "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
        "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
        "No evidence of disseminated disease",
        "Observation or Systemic therapy (category 2B)"
    ],
    [
        "Stage IA (T1abc, N0); Margins positive (R1, R2)",
        "Resection (preferred) or RT (category 2B)",
        "Surveillance (NSCL-17)",
        "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
        "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
        "Distant metastases",
        "Therapy for Recurrence and Metastasis (NSCL-18)",
        "Distant metastases",
        "Bone metastases",
        "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
        "Systemic therapy (NSCL-19)"
    ],
    [
        "Metastatic (M1) invasive breast cancer",
        "Stage IV (M1) or Recurrent disease",
        "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
        "Stage IV (M1) or Recurrent",
        "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
        "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
        "Recurrent unresectable (local or regional) or stage IV (M1) disease",
        "Bone disease not present",
        "ER- and/or PR-positive; HER2-negative",
        "BINV-22",
        "No visceral crisis and No prior endocrine therapy within 1 y",
        "Postmenopausal",
        "Systemic therapy",
        "Continue endocrine therapy until progression or unacceptable toxicity",
        "Progression",
        "Progression or unacceptable toxicity on first-line endocrine therapy",
        "Systemic therapy",
        "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
        "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
    ],
    [
        "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
        "Clinical Stage cT1–T4, 2cN0,M0",
        "Criteria for preoperative systemic therapy (BINV-M)",
        "Considering preoperative systemic therapy",
        "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
        "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
        "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
        "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
        "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
        "Preoperative systemic therapy based on HR and HER2 status",
        "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
        "BCS possible",
        "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
        "Adjuvant systemic therapy (BINV-16), no RT",
        "HR-positive/ HER2-negative",
        "ypT1–4,N0 or ypN≥1",
        "Adjuvant endocrine therapy (category 1) + adjuvant olaparib if germline BRCA1/2 mutation CPS+EG score ≥3, and residual disease (category 1). Select patients may be eligible for adjuvant abemaciclib, see BINV-K for eligibility criteria."
    ]
]